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Abstract 
 
Tele-ophthalmology is a screening alternative that facilitates compliance to eye care 
guidelines regardless of geographic constraints, promoting adequate delivery of health 
services to underserved communities. We conducted a systematic review and meta-
analysis to assess the diagnostic performance of tele-ophthalmology (TO) programs for 
the detection of diabetic retinopathy (DR), and used decision-tree modeling to explore 
its cost-effectiveness compared to in-person examination in a semi-urban scenario. 
From the 1,060 articles initially identified, 23 met inclusion criteria for data extraction. 
The diagnostic performance of TO for the detection of any DR and referable DR met the 
minimum diagnostic criteria by the Canadian Ophthalmological Society (sensitivity 
>80%, specificity >90%). Interpretation of clinical significance is limited due to significant 
heterogeneity. Considering a semi-urban scenario, the incremental cost per additional 
case of any DR detected after the introduction of pharmacy-based TO was $314.1, being 
more costly and more effective than in-person examination.   
 Keywords  
Tele-ophthalmology, tele-medicine, diabetic retinopathy screening, digital photography, 
diagnostic accuracy, meta-analysis, economic analysis, decision tree modeling.  
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1 Introduction  
Diabetic retinopathy (DR) is a sight-threatening condition involving the retinal 
microvasculature in type I and type II diabetic patients.1 Although treatments such as 
laser photocoagulation and anti-VEGF therapy can mitigate the progression of DR, it 
remains one of the main causes of vision loss and blindness in the working age 
population in industrialized countries.2,3 Screening for DR is a key component for 
timely treatment delivery, and it remains one of the main challenges to reduce cases 
of vision loss.4,5  Diabetic patients tend to be non-compliant to eye examination 
guidelines, as less than 50% attend annual screening as advised by the American 
Academy of Ophthalmology.6,7 Low availability of eye care professionals to assess 
DR, lack of awareness about the effects of diabetes on vision, and reluctance of 
undergo a dilated eye examination are among the main reasons for 
noncompliance.8,9 
Tele-ophthalmology has emerged as a promising alternative to in-person eye 
examination for DR screening.10 It uses digital photography and electronic 
communications to promote eye examination in non-specialized settings, where the 
patient and the specialist are in different geographical locations11.  This system has 
the potential to facilitate eye screening delivery to diabetic patients, while 
transferring some of the workload of routine eye care examinations from specialists 
to other settings.12 
Achieving a high diagnostic accuracy is an important factor for success in a tele-
ophthalmology screening program.13   Factors such as pharmacologic dilation, 
number of fields and population characteristics may influence the effectiveness of 
the program.14 The first objective of the present study was to quantitatively 
synthesize the evidence available regarding the diagnostic accuracy of tele-
ophthalmology strategies for DR screening, and shed some light about screening 
factors that may play a role in the correct identification of patients with DR. The 
second objective was to conduct a cost-effectiveness analysis of a pharmacy-based 
tele-ophthalmology program in type I and II diabetic adults from non-urban locations 
of Southern Ontario.  
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1.1    Structure of thesis document     
In compliance with the standards outlined by Western University School of Graduate 
and Postdoctoral studies, this thesis is presented in the integrated-article format. A 
comprehensive review of the related literature is covered in Chapter 2. The work 
comprising the thesis objectives is presented as two manuscripts. Chapter 3, 
Estimating the Diagnostic Accuracy of Tele-ophthalmology for Diabetic Retinopathy 
Screening: A meta-analysis, addresses the first objective, while Chapter 4, Cost-
effectiveness Analysis of diabetic Retinopathy Screening With Pharmacy-based Tele-
ophthalmology Versus In-person Examination, explores the second objective. Lastly, 
Chapter 5, Integrated Discussion, summarizes the main findings of this thesis in its 
global context. 
1.2    Literature cited 
1. COGAN DG, TOUSSAINT D, KUWABARA T. Retinal vascular patterns. IV. Diabetic 
retinopathy. Archives of ophthalmology. 1961;66:366–78. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/13694291. Accessed February 25, 2013. 
2. Chistiakov DA. Diabetic retinopathy: pathogenic mechanisms and current 
treatments. Diabetes & metabolic syndrome. 5(3):165–72. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/22813573. Accessed February 25, 2013. 
3. Rodriguez J, Sanchez R, Munoz B, et al. Causes of blindness and visual impairment 
in a population-based sample of U.S. Hispanics. Ophthalmology. 2002;109(4):737–
43. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11927431. Accessed January 
22, 2013. 
4. Gillow JT, Gray JA. The National Screening Committee review of diabetic 
retinopathy screening. Eye (London, England). 2001;15(Pt 1):1–2. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/11318268. Accessed March 31, 2013. 
5. Squirrell DM, Talbot JF. Screening for diabetic retinopathy. JRSM. 2003;96(6):273–
276. Available at: http://jrsm.rsmjournals.com/cgi/doi/10.1258/jrsm.96.6.273. 
Accessed May 10, 2012. 
6. American Academy of Ophthalmology. Diabetic Retinopathy Preferred Practice 
Pattern Guidelines. San Francisco, CA; 2008:39. Available at: 
http://one.aao.org/CE/PracticeGuidelines/PPP_Content.aspx?cid=d0c853d3-219f-
487b-a524-326ab3cecd9a. 
7. Zheng Y, He M, Congdon N. The worldwide epidemic of diabetic retinopathy. 
Indian journal of ophthalmology. 60(5):428–31. Available at: 
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http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3491270&tool=pmcent
rez&rendertype=abstract. Accessed January 10, 2013. 
8. Puent BD, Nichols KK. Patients’ perspectives on noncompliance with diabetic 
retinopathy standard of care guidelines. Optometry (St. Louis, Mo.). 
2004;75(11):709–716. Available at: 
http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed6&NEWS=N&A
N=15597813. 
9. Moss SE, Klein R, Klein BE. Factors associated with having eye examinations in 
persons with diabetes. Archives of family medicine. 1995;4(6):529–34. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/7773429. Accessed April 9, 2013. 
10. Yogesan K, Constable IJ, Eikelboom RH, Saarloos PP. Tele-ophthalmic screening 
using digital imaging devices. Australian and New Zealand Journal of Ophthalmology. 
1998;26:S9–S11. Available at: http://doi.wiley.com/10.1111/j.1442-
9071.1998.tb01385.x. Accessed April 7, 2013. 
11. Kawasaki S, Ito S, Satoh S, et al. Use of Telemedicine in Periodic Screening of 
Diabetic Retinopathy. Telemedicine Journal and e-Health. 2003;9(3):235–239. 
Available at: 
http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed6&NEWS=N&A
N=2003432464. 
12. JN H, Craney L, Nagendran S, CS N. Towards comprehensive population-based 
screening for diabetic retinopathy: operation of the North Wales diabetic 
retinopathy screening programme using a central patient register and various 
screening methods. Journal of Medical Screening. 2006;13(2):87–92. Available at: 
http://search.ebscohost.com/login.aspx?direct=true&db=cin20&AN=2009220293&si
te=ehost-live. 
13. Whited JD. Accuracy and reliability of teleophthalmology for diagnosing diabetic 
retinopathy and macular edema: a review of the literature. Diabetes technology & 
therapeutics. 2006;8(1):102–11. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/16472057. Accessed April 8, 2013. 
14. E Z-GI, Ran Z. Telemedicine in diabetic retinopathy screening. International 
ophthalmology clinics. 2009;49(2):75–86. Available at: 
http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=medl&NEWS=N&AN
=19349788.  
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Chapter 2  Literature review, Thesis rationale and Thesis 
objectives 
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2.1    Literature review  
Diabetic retinopathy (DR) is a serious microvascular complication in diabetic patients, 
which can have a sudden and debilitating impact on visual acuity, eventually leading 
to blindness.1,2 Features of diabetic retinopathy begin with micro-aneurysms and 
progress into exudative changes, ischemic changes, venous beading and abnormal 
vessel growth.3 Improved medical care over the last three decades (intensive insulin 
therapy and tight blood glucose control) has reduced the progress of vision-
threatening retinopathy.4 However, it remains a challenge to prevent retinopathy 
and other complications before the onset of advanced stages of disease to provide a 
timely treatment that could lead to reducing vision loss by 50%.5,6 To achieve this 
goal, it is necessary to have scheduled regular eye examinations to ensure a reliable 
detection at time when treatment (e.g. laser therapy, or anti-VEGF treatments) is 
most effective. Lack of compliance to screening guidelines, limited availability of 
retina specialists and ophthalmologists in several geographic areas and 
socioeconomic barriers are the main challenges to improve visual outcomes in 
diabetic patients.7,8        
2.1.1 Natural History of diabetic retinopathy 
Although fundamental causes are uncertain, exposure to elevated glucose and other 
risk factors initiates a cascade of biochemical and physiological changes that take 
place before the onset of vascular lesions in patients with clinically normal retinas.9 
Normal vision relies on the perfect cell-cell communication among epithelial cells on 
the retina, mainly neuronal, glial, microglial, vascular and pigmented cells (Figure 
2.1).4   Vascular changes in diabetic patients such as increased retinal flow and 
permeability of small vessels, if left uncontrolled, could lead to glucose-mediated 
microvascular damage in retinal structures conducting to progressive vision loss.2  
While the interval between diabetes diagnosis and development of any retinopathy 
varies from 4 to 7 years ( or longer), functional and anatomic changes do occur 
shortly after the onset of insulin-deficient diabetes, corresponding to the preclinical 
retinopathy stage.10–12 During this stage, early histological changes such as pericyte 
loss and basement membrane thickening are the main cellular events affecting 
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retinal function, but are only detectable by histological examination and cannot be 
identified clinically. These changes affect the growth and repair of endothelial cells in 
the retinal vascular system; pericyte loss in particular affects normal capillary 
perfusion, which increases membrane permeability and causes extravasation of 
intravascular fluid.9,13,14 To prevent the progression of this early phase to more 
severe vascular lesions, it is recommended that patients with normal-appearing 
retinas and good vision should already have a specific screening schedule as well as a 
solid preventive treatment to control for other known risk factors that could 
accelerate the onset of DR.3,4 These individuals also represent an important 
therapeutic opportunity since they will have a better response to intensive therapy 
and an increased chance to preserve vision loss.4  
 
As preclinical retinopathy remains undetected, the combined effect of pericyte loss 
and expression of angiogenic factors by nonvascular retinal cells leads to the onset of 
clinical manifestations of nonproliferative diabetic retinopathy (NPDR), such micro-
aneurysms and intraretinal microvascular abnormalities localized within the retina 
(IRMA).4,13 Other defects such as capillary dilation, nonperfusion and leakage are also 
developed predominantly in the posterior fundus temporal to the macula, 
compromising neuronal and glial cell integrity which in turn have a negative impact 
in neurotransmission.4,15 As DR progresses, new retinal vessels in the optic disc are 
formed as a consequence of the permanent expression of VEGF factor, cytokines and 
other components involved in inflammatory response. When neovascularization and 
retinal vasodilation beading takes place, the disease has progressed to proliferative 
diabetic retinopathy (PDR). The cumulative effect of vascular and neural alterations 
Figure 2.1 Anatomy of the retina 
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taking place in both the retina and optic nerve (e.g. macular edema, retinal 
detachment, optic neuropathy and axonal degeneration) along with presence of 
media opacities lead to vision loss.16  
2.1.2 Epidemiology of diabetic retinopathy 
Diabetic retinopathy is recognized as a public health problem among industrialized 
nations, as it remains the main cause of blindness in people aged 20 to 74 years of 
age. In north American adult type 2 diabetic patients older than 40 years, 40% have 
retinopathy and 8% have progressed to vision-threatening retinopathy.17 Important 
risk factors include hyperglycaemia, diabetes duration and concomitant 
hypertension.18 Vision-loss rates have been decreasing over the past three decades, 
due to the advent of photocoagulation treatment for DR patients and newer anti 
VEGF treatments. However, a timely identification of at-risk patients is of great 
importance for adequate treatment delivery.19    
2.1.2.1 Prevalence 
In many industrialized countries, DR is the most frequent cause of vision impairment 
in both the elderly and the working-age population20. A recent meta-analysis 
conducted by Yaw JWY and colleagues, revealed that the global age-adjusted 
prevalence of any DR is 34.6% (95% CI: 34.5-34.8) among diabetic patients21. A 
higher prevalence of any DR among type I DM patients was also found (77.3%), when 
compared to that of type II DM counterparts (35.2%). Similarly, prevalence estimates 
were higher in African-Americans (49.5%) and lower in Asians (19.1%); moreover, no 
significant gender difference in DR prevalence was found 21. Other studies conducted 
in United States and Australia have reported lower prevalence22. In United States the 
estimated prevalence of any DR for diabetic individuals over 40 years is 28.5%, 
whereas in Australia is 21.9% for individuals over 25 years with type II diabetes23,24. 
Of important note, rural communities seem to have particularly high DR prevalence. 
A study conducted in rural China named The Handan Eye Study, showed a 
prevalence of any DR of 40% in diabetic patients over 30 years of age25.   
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Recent studies conducted in Canada have taken place in Alberta, James Bay and the 
Metis Nation, revealing conflicting prevalence estimates.  Studies such as The 
Southern Alberta Study for Diabetic Retinopathy (SASDR)26 conducted in both urban 
and rural areas revealed a prevalence of any DR of 40%, almost two-fold greater 
than the one reported by Nathoo and colleagues (27.2%) for rural northern 
Alberta27. Similarly, a study conducted in Alberta First Nations communities by 
Rudnisky and colleagues using a tele-ophthalmology screening strategy, found a 
prevalence of any DR of 20.71%28. Such differences might be due to selection bias or 
might reflect a true difference in disease burden.  
Although it has been proposed that native communities are more susceptible to 
develop diabetes-derived vascular complications such as DR29,30, the SASDR study did 
not find differences in prevalence of any DR between native and non-native 
Canadians26.  
2.1.2.2 Incidence 
Very few population-based studies have reported the incidence of DR; the Wisconsin 
Epidemiologic Study of Diabetic Retinopathy (WESDR) is perhaps the most widely 
known31. This study conducted in the United States, included type I and II DM 
patients from 11 counties in south central Wisconsin with the main objective of 
providing a stable estimate of risk of DR according to age group (less than 30 years 
and equal or older than 30 years)32. The results showed that, in a 10-year interval  
the overall incidence of DR was 74%; 17% of patients diagnosed with DR at baseline 
developed PDR during that same timeframe33. After 25 years of follow-up (1980-
1982 to 2005-2007), almost all patients with type I diabetes developed DR (97%) 
from which 42% progressed to PDR34.  
A recent study conducted in England by Jones and colleagues, included type I and II 
diabetic patients screened by the Central Norfolk Diabetic Retinopathy Screening 
Service between 1990 and 200635. At baseline, 20.5% of patients had at least pre-
proliferative retinopathy. Overall incidence rates of any DR after 5 and 10 years of 
follow-up were 41.3% and 84.7%, respectively. Likewise, after 10 years of follow-up 
11% of patients with pre-proliferative retinopathy at baseline developed PDR. Unlike 
10 
 
 
the WESDR study results, the incidence rate of PDR was lower, probably due to a 
selective exclusion of high-risk patients that were referred to a specialist, and thus 
removed from the screening cohort35. 
While the trend of DR incidence for type I and II diabetic patients is not well 
established, there is evidence that progression to PDR has been decreasing 
throughout time6. A systematic review conducted by Wong and collaborators, 
included 28 studies from 1975 to 2008 to determine temporal trends and rates of 
progression of DR to PDR36. Among studies that reported the incidence rate after 4 
years of follow-up, the pooled incidence of PDR was 11%. After stratifying by time 
points, it was found that 19.5% of patients developed PDR in 1975-1985 in contrast 
to just 2.6% in the 1986-2008 cohort36. Such difference might be partially explained 
by the improvement in DR screening methods and treatment guidelines for diabetic 
patients, as well as a better glycemic control in recent years37.  
2.1.2.3 Risk of blindness and severe vision loss (SVL) 
Vision loss is the most important functional consequence of DR. Despite the 
availability of novel treatments to prevent severe vision impairment from DR, it is 
clear that blindness from diabetes remains a public health concern in most 
countries31,38. A meta-analysis conducted by Wong and associates, found a rate of 
severe vision loss (visual acuity <5/200)  of 2.6% in studies published between 1986 
and 200836. Moreover, SVL was more likely to develop in patients with untreated DR 
at baseline, which highlights the importance of an early diagnosis and a timely 
intervention36,39,40. .  
Also important is the burden of legal blindness (<20/200) and visual disability 
(<20/70) due to advanced forms of DR. In the WESDR study for example, 3.6% of 
insulin requiring participants were legally blind (visual acuity <20/200 in the better 
eye) at the baseline examination34,41.  Even mild forms of visual impairment have a 
considerable impact on quality of life, as patients with impaired visual acuity report 
low socialization,42 emotional distress and difficulties in physical function related to 
driving and distance vision.43 As a result, these debilitating ramifications of loss in 
visual acuity may lead to a significant reduction in the functional status of the 
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patient, taking a toll to society.9 Thus, prompt classification of DR and appropriate 
treatment according to DR severity becomes crucial to reduce its progression and to 
subside the impact on visual acuity. 
Evidence of decreasing vision loss rates has been reported in recent studies 44. Klein 
et al, reported a decrease in vision loss incidence rates in more recently diagnosed 
type I diabetic patients (annual incidence rate 1.19% in early 1980’s vs. 0.30% in mid-
2000’s), which might be due to a combined effect of better glucose controls, timely 
treatment interventions and a lower incidence of PDR45.   
2.1.2.4 Risk factors 
 
2.1.2.4.1 Modifiable factors 
 
 Hyperglycemia 
Glycemic control is currently considered an important predictive factor for DR, 
although its influence in onset and progression of DR wasn’t established until early 
1980’s.31,40 Epidemiological findings from large population studies such as WESDR,41 
the Diabetes Control and Complications Trial (DCCT),46 and the UK Prospective 
Diabetes Study (UKPDS)47 helped to determine whether the level of hyperglycemia 
influences the risk of retinopathy. Specifically, evidence from the WESDR study 
showed that for every 1% decrease in glycosylated hemoglobin A1 level (HbA1c) 
there was an association with an 18% decrease in the 21-year progression to PDR in 
insulin requiring subjects.34 This study also provided evidence that glycemic control 
was a significant predictor of 10-year rate of PDR, in both type I and II diabetic 
patients.48  
Findings from the WESDR study were further confirmed by subsequent outcomes 
from the DCCT (Type I DM patients) and the UKPDS (Type II DM patients) trials. In 
the DCCT trial, it was proven that intensive glycemic control (median HbA1c, 7.2%) 
led to a reduction of 76% (95% CI:62-85) in the development of DR among insulin-
requiring patients without DR at baseline.46 Similarly, patients in the intensive 
glycemic treatment group had a lower progression rate from early to advance DR by 
54% (95%CI: 39%-66%), as compared to patients in the conventional treatment 
group. This means that subjects with HbA1c levels of 10% have a 5-fold increase risk 
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of DR progression, as compared to patients with 7% HbA1c levels.46,49,50 In line with 
these findings, the UKPDS reported equivalent findings for type II diabetic patients.47 
After 10 years of follow-up, patients in the treatment-intensive group (dietary 
restriction plus medication) had a 25% (95%CI: 7%-40%) risk reduction of 
microvascular events (including progression of DR), when compared with the 
conventional treatment group (diet only).51,52 Levels of HbA1c were also lower in 
treatment intensive patients (7% vs. 7.9%) than in their counterparts.52 
Altogether, these studies provided evidence that intensive glycemic control is a 
determinant factor for reducing the risk of development and progression of DR in 
both type I and II diabetic patients. In fact, they founded the basis for the American 
Diabetes Association guidelines for glycemic control to reach a target level of HbA1c 
of 7% for diabetic patients.40   
 Hypertension 
It is hypothesized that hypertension might contribute to an increase of retinal blood 
flow, which in turn promotes the onset of DR.53 Some epidemiologic studies have 
found evidence of an association between hypertension and DR progression, 
although its influence in DR onset is not well established yet, especially in type I 
diabetic subjects.5,20 In the WESDR study, blood pressure was related to the 
progression of PDR in insulin-dependent patients (HR, 1.3 per 10 mmHg; 95% CI: 
1.16-1.46; p-value < 0.001), but hypertension at baseline was not associated with 
incidence of DR (HR, 1.1; 95%CI: 0.86-1.44; p-value, 0.42) in type I diabetic patients.34 
In contrast, the UKPDS study randomized eligible type II diabetic patients with 
borderline or mild hypertension to receive tight blood pressure control (<150/<85 
mmHg), or conventional control (<180/<105 mmHg).47 Patients having a tight control 
had a 34% reduction (99%CI: 11%-50%)  in the progression of DR, and a 35% 
reduction in laser photocoagulation compared with patients in the conventional 
control group52,54.  
 Other risk factors 
Results from some epidemiological studies have found that other modifiable factors 
such as dyslipidemia, obesity and inflammatory markers are somewhat associated 
with DR20,37. However, findings have been inconsistent and their particular role in the 
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pathogenesis of DR has not been yet elucidated. Although studies have failed to 
demonstrate an association of DR progression and total cholesterol levels, data from 
two large cohort studies55,56 have found that high serum lipids at baseline are related 
to the development of hard retinal exudates. Specifically, increasing triglycerides and 
lower HDL cholesterol were reported to be potential risk factors for the progression 
of DR in type I diabetic patients57,58. Such findings were also confirmed by a cross-
sectional analysis of insulin-requiring European patients, in which subjects with 
elevated triglyceride levels presented a doubled risk of DR progression, when 
compared to patients in the lowest triglyceride quartile59. 
The relationship between body mass index (BMI) or waist to hip ratio and DR 
progression is still inconclusive. Some studies have found that higher BMI and neck 
circumference are independently associated with the presence and severity of 
DR60,61. In contrast, large scale studies such as WESDR have suggested a protective 
role of BMI in DR progression among type I patients. It is evident that more research 
is needed to clarify the role of obesity in DR onset and progression62.  Similarly, 
evidence regarding the role of inflammatory markers as risk factors for DR is at an 
early stage, in which markers of inflammation such as C-reactive protein, interleukin-
6 and soluble intercellular adhesion molecule 1 have been associated with 
retinopathy and proposed as novel therapeutic targets as well60,63. Compelling 
epidemiologic evidence is necessary to understand the role of markers of 
inflammation in DR pathogenesis and the possibilities of clinical use as therapeutic 
targets for retinopathy prevention. 
2.1.2.4.2 Non-modifiable factors 
 
 Duration of diabetes 
The role of diabetes duration in the development of DR is well established, and has 
been consistently demonstrated in several studies.5,6,20,64,65 For instance, two 
population studies conducted in the United States reported increased DR among 
patients with ≥ 15 years of diabetes. The Los Angeles Latino Eye Study (LALES) 
reported a four-fold increased incidence of DR in the first eye for patients with more 
than 15 years of diabetes as compared to individuals with newly diagnosed 
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individuals (p=0.004).64 In line with these findings, Harris and collaborators showed a 
higher prevalence of DR in type II diabetic patients with 15 or more years since 
diagnosis versus subjects with less than 5 years of diabetes (36% and 11.8% 
respectively, p <0.001).66   
 Ethnicity 
Research studies have demonstrated some disparity in the prevalence and severity 
of DR among ethnic groups, which sometimes has been independent from other 
known risk factors.6,67 Some studies conducted in the United States have reported 
that members from Hispanic and African American communities have a greater risk 
of DR when compared to non-Hispanic white counterparts.64,66,68 For example, the 
Multi-ethnic study of Artherosclerosis (MESA) reported a higher DR prevalence (p= 
0.01) among black and Hispanic people (36.7% and 37.4%, respectively) than in white 
subjects (24.8%). Although ethnic origin was not an independent predictor of DR, 
researchers have speculated that genetic factors might explain the excess risk of DR 
in some ethnic groups.17,49,51,52 In a subsequent analysis, the DCCT study investigators 
assessed familial associations and risk of DR in more than 300 participants69. It 
showed an increased risk of severity of retinopathy among relatives of retinopathy-
positive patients when compared to relatives of retinopathy-negative subjects (OR= 
3.1; p < 0.05).69  
Altogether, such evidence suggests that differential genetic predisposition to 
microvascular damage, or even intrinsic cultural factors among ethnic groups might 
have an underlying role in the development of DR. However, greater exposure to 
hyperglycemia and higher frequency of risk factors (i.e. poor glycemic control) in 
African Americans and Hispanic individuals versus white subjects might also account 
for reported differences in DR development among ethnic groups66.  
 Other non-modifiable risk factors 
It is speculated that hormone elevation levels occurring after puberty are positively 
associated with retinopathy70. Studies conducted in the past two decades reported 
that prepubertal duration of diabetes is related to increasing the delay in the onset 
of microvascular complications, such as DR in insulin-requiring patients.71–73 A 
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subsequent analysis derived from the WESDR study, reported that diabetes duration 
after menarche was associated with an increased risk of retinopathy compared with 
diabetes duration prior menarche (OR=3.15; p< 0.05).71 Similarly, pregnancy has 
been associated with an increased development and progression of DR, especially in 
type I diabetic patients.74,75 In a longitudinal analysis derived from the DCCT study, 
pregnant women (type I diabetes) had 1.6 to 2.4-fold increased risk of retinopathy 
compared to non-pregnant counterparts, being the highest risk at the second 
semester.76 Notwithstanding, DR developed during pregnancy shows a 30% to 50% 
rate of spontaneous regression after delivery with no long-term consequences.77 
2.1.3 Clinical assessment of diabetic retinopathy 
2.1.3.1 Screening techniques 
A comprehensive screening evaluation for DR should include intraocular pressure 
and visual acuity estimations, as well as retina examinations for the presence of 
neovascularization.78 The main potential screening modalities for DR assessment are 
ophthalmoscopy (direct and indirect), fluorescein angiography, slit-lamp 
biomicroscopy and mydriatic or non-mydriatic camera-based screening.79 According 
to the Canadian Ophthalmology Society evidence-based guidelines, screening 
alternatives for DR grading should accomplish a sensitivity of at least 80% and 
specificity between 90% and 95%, if performed by a trained examiner.78 Likewise, a 
widely used clinical standard proposed by the British Diabetic Association Working 
Group in 1997 specifies that methods of screening for DR should match the 80% and 
95% specificity standards, keeping in mind that lower effectiveness values imply 
potential costs for the healthcare system and missed treatment opportunities.80    
From the mentioned alternatives, ophthalmoscopy and slit-lamp biomicroscopy are 
traditionally used for community-based screening. However, ophthalmoscopy shows 
a significant variation on the effectiveness depending on the healthcare professional 
that conducts the examination.81 For example, studies that evaluated the 
effectiveness of screenings by optometrists and general practitioners showed that 
sensitivity levels for detecting sight-threatening retinopathy ranged between 25% 
and 80%, being optometrists more effective than general practitioners.82–84 Similarly, 
studies using undilated ophthalmoscopy screening conducted by 
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nonophthalmologists reported poor performance, with a sensitivity as low as 50% 
for the detection of PDR.81 Alternatively,  the best screening approach for grading DR 
is dilated slit-lamp biomicroscopy, assessed by a retina specialist or senior 
ophthalmologist with a 90D or 78D lens. This technique has proven to be highly 
effective, achieving sensitivity and specificity values of 87% and 94%, 
respectively.83,85  
2.1.3.2 Screening and prevention of DR 
DR fulfills the World Health Organization (WHO) criteria for screening;86 these 
criteria revolve around three critical components: Disease, screening test, diagnosis 
and treatment. 
Disease 
DR is an important public health concern,87 with a recognizable presymptomatic 
stage and a natural history well described in the literature.2 It is widely accepted that 
DR presents a long preclinical phase that may last up to 7 years, during which the 
patient cannot detect any vision changes.10-12 Usually, the patient seeks medical care 
after severe retinal damage has occurred, for which treatment may not be effective. 
9 Therefore, the detection of early stages of DR through screening facilitate adequate 
treatment delivery, which is translated to cases of blindness prevented. For example, 
some districts in Great Britain with long-standing DR screening programs have 
reported that DR is no longer the main cause of blindness amongst working-age 
individuals, as opposed to other settings that do not have a consistent screening 
program in place.7   
Screening test 
Several screening methods can be used for DR examination. Screening typically 
includes direct/indirect ophthalmoscopy, slit-lamp biomicroscopy or digital fundus 
photography. Their performance may vary depending on use of pharmacologic 
dilation, the grade of expertise of the examiner and threshold positivity. For the 
detection of sight-threatening retinopathy, mydriatic digital fundus photography 
results interpreted by an expert reader yield a sensitivity and specificity of over 
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80%.82 These screening techniques are not invasive and do not cause the patient any 
harm; however, pharmacologic mydriasis may cause temporary blurred vision and 
increase the risk of temporary open-angle glaucoma.39 Nevertheless, the benefits of 
early detection of DR cases outweight the potential (and reversible) harm of open-
anle glaucoma.9       
Diagnosis and treatment 
Several landmark clinical trials32,88,89 have shown the clinical benefits of timely and 
accurate screening that facilitates treatment delivery and prevents blindeness due to 
DR. For example, the Diabetic Retinopathy Study (DRS) demonstrated that panretinal 
photocoagulation reduces the risk of vision loss by 50%  and 16% in patients with 
macular edema and PDR, respectively.90 Such findings were later confirmed by the 
ETDRS study in older-onset diabetic patients.91 Even novel therapies, such as anti-
VEGF treatments have shown improvement in visual acuity in patients with diabetic 
macular edema, a serious complication derived from the progression of DR.92  More 
recent studies on anti-VEGF treatments have shown that not only patients under this 
therapy have a long-lasting improvement in visual acuity, but also have significant 
regression of retinal neovascularization and reduced retinal thickness.93 Therefore, 
an early intervention for DR treatment does translate in clinical improvement by 
preventing cases of blindness and severe vision loss in patients with moderate PDR.90 
In fact, evidence-based models have shown that with proper screening and 
treatment, 6% of patients would be prevented from blindness within a year and up 
to 34% within 10 years..   
 Finally, DR screening programs have proven to be cost-effective in economic 
modelling studies, resulting in substantial budget savings for the healthcare 
provider.94,95  
Screening goals and challenges 
The main goal of a screening program for DR is the detection of sight-threatening 
disease, in which the detection of any retinopathy is of secondary benefit but may 
act as an early proxy of the former.96 Examination guidelines have been developed 
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by organizations such as the American Academy of Ophthalmology (AAO)97 and the 
American Diabetes Association (ADA)19 which have been largely based on 
retinopathy severity.  According to ADA’s latest guidelines, an immediate eye 
examination is recommended for newly diagnosed type II diabetic patients, whereas 
type I patients can have their first examination within 3 to 5 years of diagnosis. 
Annual or biannual eye examination is recommended in absence of complications, 
with more frequent examinations in case of abnormal findings.19 Likewise, the AAO 
formulates the same differential recommendation for type I and II diabetic patients, 
with an annual follow-up examination for both groups.97 
Adherence to examination recommendations has been less than satisfactory, with a 
30%-60% compliance rate that varies across different settings98. For instance, 
adherence rates to vision guidelines in North America were less than 50% during the 
past two decades;8 unfortunately, reported rates do not yet show an increasing 
adherence trend over time.99 Studies also show that translation of research into 
practice and adoption of examination guidelines have been delayed by compliance 
barriers, in areas such as community education and finance.100 Among these studies, 
the Diabetic Retinopathy Awareness Program (DRAP) trial101 conducted in the US, 
reported a nonadherence rate to AAO and ADA guidelines of  30% (n= 813/2308). It 
also suggested four main factors associated to poor compliance: healthcare provider, 
population demographics, diabetes type and duration and education.101 Low 
screening rates translates into negative implications for the quality of life of diabetic 
patients, representing potential expenditures to their clinical care, lost productivity 
and lost opportunities for vision loss prevention.8 
Overall, this evidence supports the need to improve vision care practices in diabetic 
patients, with greater emphasis on target groups at high-risk of nonadherence.100,101 
These groups are typically from rural or remote areas and have a low level of 
awareness about vision complications of diabetes; improved access to healthcare 
(practice/provider performance) and more detailed information about DR 
complications would increase screening attendance.102,103   
2.1.3.3 Grading of diabetic retinopathy severity 
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Currently, there are many validated DR grading scales that are applied widely in 
clinical and research settings, which are based on the identification of key 
microvascular abnormalities from each DR stage (Figure 2.2).12,104,105 Among 
available guidelines, the Airlie House classification is universally accepted in research 
settings and publications, for it has demonstrated a satisfactory reproducibility and 
validity.88 It is based on seven standard 30-degree photographic fields, yielding an 
accurate representation of the retinal status; an extensive standard set of more than 
11 DR definitions is employed to classify DR severity in patients.88 In spite of its use in 
clinical trials as the “gold standard” for DR screening, the implementation of the 
Modified Airlie House classification in the clinical setting and mass screening is 
somewhat unpractical due to its complexity and meticulous definitions, which are 
unnecessary and difficult to remember in clinical care.104,106 In fact, the American 
Academy of Ophthalmology has found that most health professionals do not use the 
full Airlie House classification scale due to its complexity.12  
Consequently, several countries have adapted and simplified this classification for 
general practice, resulting in a variety of validated guidelines, such as European field 
guide, Winsconsin guidelines and EURODIAB protocol, which have been used in 
different settings over the past decade (Figure 2.2).12,104,105 It is also common to find 
published studies in which authors modify an existent grading guideline, or even 
develop their own classification to grade severity of DR in their study patients.107,108  
The lack of consensus regarding DR severity classification poses a challenge in 
healthcare delivery and research, limiting the worldwide exchange of information 
and data.109,110 For example, the comparison of screening strategies from different 
settings would be inappropriate if each study used their own grading system. It also 
affects the effective communication between and among primary care physicians, 
nurses, ophthalmologists and other eye care providers, which would be improved if a 
standard set of definitions of severity of diabetic retinopathy is universally 
implemented.12,106,111 
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In an effort to providing a single standardized practical clinical DR severity scale for 
worldwide use, the AAO launched a project in 2001 to develop an optimal DR scale, 
resulting in the publication of the International Clinical Diabetic Retinopathy and 
Diabetic Macular Edema Disease Severity Scales in 2003.12 Based on landmark 
studies such as ETDRS88 and WESDR32, this scale comprises 5 different levels  of DR 
disease severity according to findings of IRMA and venous beading lesions (Figure 
2.2). It is expected that the system will be implemented by ophthalmologists and 
other healthcare providers, who can also promote its dissemination and future 
incorporation of the International DR Scale in practice guidelines.12,78,112  
2.1.3.4 Gold standard for diabetic retinopathy screening 
From the existing screening alternatives, ETDRS 30-degrees 7-field stereo color 35 
mm slides is considered the gold standard for detection of DR.94 This technique was 
initially used in the DRS trial113 (1976), later expanded in the ETDRS trial88 (1991) and 
validated in subsequent studies. It consists of a set of 7 photographs taken in 
different areas of the eye, including stereoscopic photographs centered on optic 
disc, macula, temporal to the macula, and upper and lower poles of the disc.88 This 
method allows a detailed examination of various retinal abnormalities including 
micro-aneurysms, soft exudates, hard exudates and retinal haemorrhages. However, 
this technique is labour intensive, time consuming (it takes several weeks from data 
Figure 2.2   Diabetic Retinopathy Disease Severity Scales. ETDRS= Early Treatment Diabetic 
Retinopathy Study DR= Diabetic Retinopathy NPDR= Non-proliferative Diabetic Retinopathy 
PDR= Proliferative Diabetic Retinopathy 
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acquisition to interpretation), and requires skilled photographers and sophisticated 
photography equipment.114 Consequently, it becomes impractical for community 
screening and is not universally used in routine clinical care.79  
Despite these limitations, some experts consider the ETDRS photograph protocol as 
the only accepted gold standard test for detecting diabetic retinopathy in 
research,79,114,115 although this statement is not universally recognized. Validation 
studies have demonstrated that slit-lamp examination by an experienced specialist is 
equivalent to ETDRS photographs in the detection of referable retinopathy; hence, 
slit-lamp biomicroscopy has been used as a reference standard as well. In a study 
conducted by Scanlon and colleagues116  in which slit-lamp biomicroscopy performed 
by an ophthalmologist was assessed against 7-field ETDRS photographs, sensitivity 
and specificity values of 87.4% and 94.9%, respectively. Hence, authors concluded 
that slit-lamp biomicroscopy if performed by an experienced ophthalmologist is 
favourably compared with 7-field ETDRS photographs in the detection of referable 
retinopathy.116 Other studies have also showed a high level of agreement (kappa 
index > 0.75) between examination and 7-field ETDRS photographs for grading 
severe forms of DR, with small number of disagreements of clinical significane.117,118  
Given that a dual gold standard exists, diagnostic accuracy studies have reported the 
use of either ETDRS photographs or slit-lamp biomicroscopy as the gold standard 
test.115 Such contrast is explained by the fact that observational studies prefer slit-
lamp biomicroscopy as the reference standard to assess diagnostic accuracy of DR 
screening alternatives, especially if the study is performed “in the field”. These 
projects are often conducted in remote areas and isolated communities, where 
transportation of the specialized equipment required for stereo 7-field ETDRS 
photographs becomes impractical and unsuitable for large-scale screening.119,120 
2.1.4 Digital retinal photography 
During the past 30 years, digital photography has been introduced as an effective 
alternative to ophthalmoscopy and traditional camera-based screening for DR 
screening programs. With the advent of digital and mobile technology, it has 
gradually become the preferred screening option, as digital cameras have technically 
22 
 
 
improved and become less expensive.121 In addition to the advantages of camera-
based screening (having an image record, review of disease progression and quality 
assurance), digital images can be immediately assessed and better quality images 
can be retaken if necessary.96 With digital cameras it is also possible to transmit the 
images electronically to specialized centers where ophthalmologists can review them 
and grade the presence and extent of DR.122  
Given the advantages of digital retinal photography, a growing number of studies 
have assessed its performance for DR screening in diverse settings; most results have 
been promising, reporting a sensitivity and specificity of above 80%123–125 with some 
exceptions, where effectiveness was lower than 60%.126 Such a contrast among 
studies also show that the chosen technology (i.e type of camera, resolution, image 
compression), number of fields taken and use of pharmacologic dilation might play 
an important role on the effectiveness of digital retinal photography screening.127 
Usually, nonmydriatic approaches have a lower sensitivity and a higher rate of 
unreadable photographs than those using pharmacologic dilation. Baeza and 
collaborators128 directly addressed this issue by assessing three different screening 
strategies with and without pharmacologic dilation, using a nonmydriatic digital 
camera. Compared with 7-field ETDRS photographs, strategies using mydriasis 
achieved a sensitivity between 82%-85% and a specificity of 98% with a 2% failure 
rate, whereas nonmydriatic approaches showed a sensitivity range of 67%-82% and a 
specificity of 99% with a 16% failure rate.128 Of important note, the screening 
strategy that used only one filed and no pharmacologic dilation had the worst 
sensitivity (67%; 95%CI: 54%-80%).  
In contrast, other studies have reported that the use of a single field does not affect 
screening quality as long as pharmacologic dilation is used. A study conducted in 
Canada119 evaluated the effectiveness of single field digital screening in an aboriginal 
community at James Bay (Ontario), since this modality is very practical and easy to 
perform in remote areas. Authors found that this single-field approach would be 
impossible to conduct without pharmacologic dilation in this community, given the 
high failure rate (> 50%). However when pharmacologic dilation was implemented, 
the failure rate improve dramatically (1.5%) and effectiveness values for detecting 
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referable retinopathy met the Canadian Ophthalmological Society’s standards 
(sensitivity >80%, specificity between 90% and 95%).119      
Although there is some evidence of the importance of pharmacologic dilation and 
number of fields used in digital photography screening for DR,128,129 the extent of this 
influence and the interaction between both components is not well defined.81 
Moreover, the role of other technical characteristics such as camera type, resolution, 
image compression and storage on digital photography screening is unclear. So far, 
current guidelines from the Canadian Society of Ophthalmology and the AAO 
recommend that for digital photography screening, at least two 45° fields should be 
taken with pharmacologic dilation if mydriatic cameras are used, and without pupil 
dilation for the nonmydriatic camera models.78,79  
2.1.5 Tele-ophthalmology assessment of diabetic retinopathy (telescreening) 
Tele-ophthalmology is an area of telemedicine that allows the examination of 
patient’s eye problems with the patient and eye care specialist located in different 
geographical areas. This method is based on the exchange of medical information 
from one site to another using electronic communications.114 It has been described 
as a promising alternative that improves access to screening regardless of geographic 
constraints; it also reduces travel time and cost while creating new screening 
opportunities in underserved communities.130  
Although considered futuristic and experimental during the early 80’s, tele-
ophthalmology has gradually evolved into a specialty that incorporates modern 
technology with the potential of becoming an integral component of primary care of 
diabetic patients.131 Diabetic retinopathy telehealth programs typically encompass 
four elements of care: Image acquisition, image review and evaluation, patient care 
supervision, and image (data) storage.132  
Technical requirements may vary, depending of each screening program scope and 
intent.133 In a general tele-ophthalmology program for DR screening (store-and-
forward model), retinal images are obtained with digital retinal cameras (mydriatic 
or non-mydriatic) by a previously trained non-specialist in a remote place.114 The 
data is then securely transferred to a reading center for evaluation, in which ocular 
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assessment is performed by an eye specialist or a certified reader; specifications 
regarding image compression, bandwidth, encryption and error checking 
mechanisms are tailored according to each screening program.132 Finally, findings are 
reported back to the primary care physician with the recommendation regarding the 
need for referral.134  
In some cases images may be of poor quality due to presence of media opacities, 
small pupil size or technical difficulties.129 In telescreening for DR, unreadable images 
are considered positive findings and patients must be referred for a comprehensive 
evaluation.135 To overcome this issue, the use of pharmacologic agents for pupil 
dilation may be incorporated in the screening protocol. However, the use of 
mydriatic agents by nonophthalmic personnel may represent an issue in that adverse 
events such as angle-closure glaucoma might occur, requiring the need of specialized 
personnel.119,136  
2.1.5.1 General tele-ophthalmology guidelines 
Tele-ophthalmology is a mature telehealth specialty with well-established standards 
defined by the American Telemedicine Association (ATA), which seeks to improve 
healthcare delivery through telecommunications and information technology, while 
eliminating barriers to the use of telemedicine.132 According to the ATA, the main 
goals of a tele-ophthalmology program for DR are to “reduce the incidence of vision 
loss due to DR, improve access to diagnosis and management of DR, decrease the 
cost of identifying patients with DR”.135 As clearly stated by the American 
Telemedicine Association135 and the American Academy of Ophthalmology97, retinal 
telemedicine examination is currently not intended to replace a comprehensive eye 
examination by an experienced ophthalmologist, but to act as a first-line screening 
tool for DR that will filter and reduce the volume of unnecessarily referred patients.   
Tele-ophthalmology systems are categorized into three groups depending on image 
transmission: Real-time, store-and-forward, and hybrid. Real time transmission 
involves a two-way real time video connection, whereas in store-and-forward 
teleconsultation the image is first captured with a digital camera in a fixed or mobile 
telescreening unit and then sent forward via electronic communications.137 Hybrid is 
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the combination of the two former approaches.138 Current ocular telehealth practice 
guidelines from the American Telemedicine Association are based on the store-and-
forward modality.135  
2.1.5.2 Clinical validation of tele-ophthalmology systems 
 
Both the AAO85 and the ATA135 have stressed the importance of performing pilot 
studies for the validation of new tele-ophthalmology programs. This validation must 
state the scope of the program, target population, aimed validation category and 
technology used. Ideally, results should be published in a peer-review journal in 
which sensitivity, specificity and agreement values are reported.132,139 It is 
considered that the current benchmark for evaluating a tele-ophthalmology program 
consists on the use of 7 field ETDRS photographs as the reference standard, and the 
use of the International DR Disease Severity Scale as the guideline for DR 
classification.12,88  
To outline a standard for the validation process, the ATA recently published the 
second edition of “Telehealth practice recommendations for diabetic 
retinopathy”135, in which four categories for validation of tele-ophthalmology 
programs for DR are documented (Table 2.1). Each one differs in hardware and 
software technology requirements, the level of expertise of staffing and support, and 
clinical outcomes. Those programs with low thresholds for referral need not follow 
strict DR classifications and technological requirements are simpler compared to 
those programs that seek to discriminate level of DR.140 Independently of the 
validation category, tele-ophthalmology programs should have less than 10% rate of 
unreadable images.78 
Currently, there are no tele-ophthalmology programs that meet category 4 criteria 
which would allow the replacement of a comprehensive in person assessment. 
However, mature tele-ophthalmology programs for DR screening in the US (more 
than 10 years old) already have a category 3 validation in which level of DR is 
assessed, instead of the simpler dichotomous classification of category 1 and 2 
programs.132   
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Several tele-ophthalmology programs for DR screening have been launched among 
different settings and target populations in Australia141, United Kingdom142, France 
and United States143. For example, Australian models are focused on the rural 
setting, where underserved communities get a screening examination 900 km away 
from the specialized center.144 Alternatively, tele-ophthalmology is also being used 
for inmate follow-up examinations in a Texas prison, saving ground transportation 
times and minimizing security requirements.145 In North America, the Joslin Vision 
Network (JVN) located in Boston (MA) is an example of a validated category 3 
program, with the main objective of providing adequate eye care to US veterans 
from the US Veteran’s Administration.143 The JVN program has also been 
incorporated into the Phoenix Indian Medical Center, providing diabetic eye care for 
Native Americans living in reservations.146  
2.1.6 Concluding remarks 
There are currently 347 million diabetics worldwide, from which 33% have signs of 
DR. About 50% of diabetic patients seek eye examinations, whereas the remaining 
50%  are still at risk of blindness from DR.6 Unfortunately, Canada is not the 
exception.78 According to a recent study conducted by Boucher and collaborators, 
the rate of diabetic patients who are noncompliant to DR Canadian guidelines is 68% 
in Quebec, Manitoba, Saskatchewan, Alberta and British Columbia. Moreover, 38% 
of diabetic patients in the mentioned provinces have never had an eye 
examination.147 Besides lack of awareness regarding diabetic eye complications, 
Table 2.1 Validation categories for Diabetic Retinopathy telescreening programs  
(American Telemedicine Association) 
ETDRS= Early Treatment Diabetic Retinopathy 
1 American Telemedicine Association (2011) 
2 Telehealth methods for diabetic retinopathy and glaucoma. ARVO education course. May 4, 2013 
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inaccessibility and difficulty of getting an appointment for screening is another main 
reason for not getting a screening examination.138  
Discrepancies in access to eye care are unlikely to subside in the future. As the 
incidence of diabetes increases over 50%, the growth in the number of 
ophthalmologists in North America is dismal (less than 2%).148 Consequently, an 
increasing number of patients will require an eye care examination at least every 
two years but even less eye specialists would be available to fulfill the demand for 
eye care.106 Public health agencies will be unable to meet DR screening guidelines 
relying exclusively on the traditional in-person examination.  
2.2    Thesis rationale  
As described previously, tele-ophthalmology is an emerging alternative for DR 
monitoring, and is being explored in many  geographic settings and across several 
scenarios of  in-place physician accessibility.114 Multiple studies have evaluated the 
effectiveness of ongoing tele-ophthalmology programs by means of assessing 
diagnostic accuracy estimates such as sensitivity, specificity and kappa values. The 
methods and settings vary widely among studies; equipment specifications and cut-
off criteria also differ according with program needs and available technology.  
To date, only three reviews have attempted to systematically summarize the 
effectiveness of screening programs for DR monitoring.81,127,149 The first quantitative 
review was published in 1996, before the advent of tele-ophthalmology for DR 
care.149 Later, Hutchinson and colleagues81 published a systematic review on 
effectiveness of screening tests for DR which included 20 studies from 1987 to 1999. 
They concluded that mydriatic retinal photography was the most effective strategy 
for DR screening, even when compared to direct and indirect ophthalmoscopy.81 
However, the authors did not perform a meta-analysis to estimate the diagnostic 
accuracy of mydriatic retinal photography. In one recent review, Bragge et al 
reported a meta-analysis of tests designed to detect presence or absence of DR.127 
Using a hierarchical logistic regression approach, the overall sensitivity and 
specificity was 82.5% (95%CI: 75.6-87.9) and 88.4% (95%CI: 84.5-91.4), 
respectively.127 The study was limited only to studies that assessed the presence of 
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any DR, whereas studies that evaluated the presence of referable retinopathy were 
not quantitatively summarized. More importantly, methodological quality of 
included studies was not assessed in this review.  
Of note, none of these reviews were tailored to synthesize the evidence of tele-
ophthalmology programs; on the contrary, they assessed all DR examination 
strategies besides digital photography. Their scope included many screening 
methods such as in-person examination (ophthalmoscopy), film camera, and 
polaroid camera, which are not suitable for telemedicine.135 Hence, evidence of the 
effectiveness of tele-ophthalmology programs for DR assessment has been 
accumulating with no conclusive remarks. Furthermore, the use of pharmacologic 
dilation and number of fields necessary to maximize the effectiveness of tele-
ophthalmology screening still remains controversial.78,120 A systematic appraisal of 
the literature considering the influence of mydriasis and number of fields on tele-
ophthalmology programs is deemed necessary. 
Equally important is the estimation of the economic impact of these programs and 
the potential long-term benefits that may justify such investment. Several cost-
effectiveness studies have assessed the impact of screening programs for diabetic 
retinopathy, from which a small subset focused on the economic evaluation of tele-
ophthalmology technologies.94,145,150 A recent review of the economic evidence of 
diabetic retinopathy151 included 13 cost-effectiveness studies that aimed to compare 
key features of a DR screening program such as opportunistic screening as opposed 
to systematic screening, screening frequency and incorporation of new effective (but 
more costly) technologies for screening delivery. In general, studies have concluded 
that the implementation of DR screening programs is cost-effective.152–154 However, 
the clinical and economic effectiveness of tele-ophthalmology is still uncertain, 
depending heavily on patient compliance, the workload for each retinal unit and the 
scenario in which would be implemented (urban or non-urban).151,155,156   
 In Canada, well-developed tele-ophthalmology programs are operating in the 
provinces of British Columbia, Vancouver and Quebec.78 With the goal of creating 
new eye screening opportunities and promote regular attendance among diabetic 
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patients, most programs have been implemented in remote settings that do not 
have ophthalmologists on-site.157,158 Although not a substitute for comprehensive 
eye examination, tele-ophthalmology act as a filter to identify and timely refer 
patients in need for a specialist examination.135  
Interestingly, no telescreening initiative has been taken to improve eye care 
coverage for diabetic patients in a non-urban setting. Given the significant capital 
investment that such an initiative would demand, an economic analysis would aid to 
explore whether tele-ophthalmology is the best alternative for this specific context. 
2.3     Thesis objectives  
This thesis encompasses two different, yet highly dependent studies. The overall aim 
is to determine the diagnostic accuracy of tele-ophthalmology strategies for diabetic 
retinopathy screening, and to explore the cost-effectiveness of a pharmacy-based 
tele-ophthalmology screening program for detection of diabetic retinopathy in non-
urban Southern Ontario. 
Objective 1 – Meta-analysis 
a) To systematically identify, review and quantitatively synthesize the evidence 
available pertaining to the diagnostic accuracy of tele-ophthalmology strategies for 
DR screening in adults as compared to reference standards (7 field ETDRS 
photographs or slit-lamp biomicroscopy). 
b) To explore screening and study design factors that may influence the diagnostic 
accuracy of tele-ophthalmology assessments such as pharmacologic dilation, number 
of fields used, choice of reference standard and risk of patient selection bias.  
Hypothesis Tele-ophthalmology programs meet the minimum effectiveness 
requirements advised by the Canadian Ophthalmological Society (sensitivity over 
80%, specificity between 90% and 95%).78 
 
 
30 
 
 
Objective 2 – Cost-effectiveness analysis 
To explore the cost-effectiveness of a pharmacy-based tele-ophthalmology program 
compared to primary care consultation (ophthalmoscopy) for diabetic retinopathy 
screening in Southern Ontario (Chatham-Kent region). 
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3.1   Introduction 
Diabetic retinopathy (DR) occurs as a microvascular complication that affects the 
blood vessels in the retina of diabetic patients, leading to a high risk of blindness if 
left untreated.1 Although treatments for DR are effective, economic, and available 
within the public health system, it remains the leading cause of legal and functional 
blindness for working-age adults in industrialized nations, representing 4.8% of cases 
of vision loss worldwide.2,3 Early detection by regular screening for DR is a key factor 
for its timely treatment, helping to prevent blindness and other impaired visual 
conditions in diabetic individuals.4 However, only 50% of patients with diabetes 
mellitus (DM) follow the screening recommendations by the American Diabetes 
Association.5 
Within this context, tele-ophthalmology has emerged as a possible alternative that 
facilitates compliance to evidence-based medicine, perhaps without geographic 
constraints. It may improve consistency of healthcare in a cost-effective fashion.6–8 
Tele-ophthalmology screening initiatives for DR have been tested and launched in 
diverse settings as an attempt of providing specialized eye care to underserved 
communities regardless geographic limitations, while also eliminating unnecessary 
traveling for patients and specialists.9,10  
Published studies have focused on the diagnostic accuracy of digital imaging 
screening for DR in diverse settings for its use in store-and-forward tele-
ophthalmology strategies.9,11 A literature review reported that sensitivity and 
specificity of telescreening for detecting DR has been consistently high, and 
concluded that this model appeared to be a suitable test for DR assessment.12 Other 
reviews have addressed the diagnostic accuracy of diverse screening methods for 
DR, including digital camera, film camera, direct examination and polaroid camera 
assessments.13,14 Nevertheless, evidence on diagnostic accuracy of DR screening 
focused on tele-ophthalmology strategies has not been critically synthesized in a 
systematic review or meta-analysis. 
Likewise, research and validation studies have also explored the influence of tele-
ophthalmology components, namely,  pharmacologic dilation, number of fields, 
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automated grading and image compression to assess their impact on screening 
diagnostic accuracy.15–17 However, there has been much discussion about the most 
effective method for detecting DR in the telemedicine context, since current 
evidence on this topic is contradictory and sometimes inconclusive.18,19 Bringing 
these studies together and synthesizing their results, will promote a better 
understanding of their clinical usefulness and influence on the diagnostic 
performance of tele-ophthalmology programs.     
 Furthermore, the choice of gold standard for tele-ophthalmology validation studies 
has been a subject of debate among specialists,20 who claim that the current 
recommendation (standard 7 field ETDRS photographs) is impractical in rural 
settings.6,21 Given the current gaps in the literature and the need of evidence 
synthesis on this field, the present meta-analysis seeks the following objectives: 1) to 
systematically identify, review and quantitatively synthesize the evidence available 
pertaining to the diagnostic accuracy of tele-ophthalmology strategies for DR 
screening in adults as compared to reference standards, and 2) to explore screening 
and design factors that influence the diagnostic accuracy of tele-ophthalmology 
assessments, namely pharmacologic dilation, number of fields used, choice of 
reference standard, type of diabetes and risk of patient selection bias. Hence, we 
hypothesized that tele-ophthalmology programs meet the minimum effectiveness 
requirements advised by the Canadian Ophthalmological Society (sensitivity over 
80%, specificity between 90% and 95%).22 
3.2 Methods 
We conducted and reported this meta-analysis in compliance with the Meta-analysis 
of Observational Studies (MOOSE) recommendations (Appendix A) and Preferred 
Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines 
(Appendix B). 
3.2.1 Literature search 
A structured search was conducted among six different databases (Medline, 
EMBASE, CINAHL, BIOSIS, Web of Science, Cochrane Library) from January 1998 to 
June 2012 (last update on January 2013), without language restrictions. Free text key 
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words and medical subject headings were tailored to each of the electronic 
databases, and included four main domains: diabetic retinopathy, diagnosis, 
telemedicine and evaluation studies (see list of search terms for all databases in 
Appendix C). A health information specialist (JC) contributed to the development of 
the search strategy, in consultation with other team members including content 
experts. Grey literature was addressed by manually searching electronic abstracts 
and dissertations from The American Academy of Ophthalmology, the Association 
for Research in Vision and Ophthalmology (ARVO) meetings. As a complementary 
search, bibliographies of eligible studies and relevant systematic reviews retrieved in 
the literature search were manually screened.23 All citations from each database 
search were exported to the reference manager program EPPI version 4.3 (EPPI 
Centre, Institute of Education, London, UK), for de-duplication and screening. 
3.2.2 Eligibility criteria 
Primary studies reporting sensitivity and specificity outcomes of a tele-
ophthalmology strategy for DR diagnosis were included; we focused on those studies 
that explicitly reported sensitivity and specificity estimates for the detection of any 
retinopathy and/or referable retinopathy amongst adult patients with type 1 or type 
2 diabetes. In the present review, any approach that promoted the screening of DR 
by store-and-forward transmission of digital images, with the patient and the 
ophthalmologist being in different geographical settings was considered a tele-
ophthalmology strategy.6 The exclusion criteria were: (i) studies addressing pediatric 
patients (< 18 years old), (ii) editorials, commentaries and opinion articles, (iii) 
studies conducted in under-developed, developing or non-industrialized settings 
(Latin America, Eastern Europe, Africa and most Asian countries), (iv) studies with a 
reference standard different from 7 field ETDRS photographs or slit-lamp 
biomicroscopy, v) studies with less than 20 fully-screened patients. 
3.2.3 Article screening 
The screening strategy involved a two-step process. First, titles and abstracts were 
reviewed to identify potentially relevant articles.  Next, full-text articles from 
included citations were retrieved to closely assess inclusion and exclusion criteria. 
51 
 
 
Two reviewers (AC and HS) screened citations and full-text articles in an independent 
fashion, and Cohen’s kappa coefficients were used to examine inter-rater 
agreement. We interpreted kappa values as follows: 0.40 to 0.59 reflect fair 
agreement, 0.60 to 0.74 reflect good agreement, and ≥0.75 reflect excellent 
agreement.24,25 Discrepancies were reconciled by discussion and any remaining 
disagreements were solved through consultation with an experienced 
ophthalmologist (WH), who assessed study eligibility. Articles published in language 
other than English were initially addressed by a translator (AC for Spanish articles, 
WG for French articles and independent translator for German articles) who 
examined the title and abstract and determined the study relevance based on first 
level screening questions. 
3.2.4 Data extraction and quality assessment 
A data extraction form was created and piloted with a subset of eligible studies. 
Based on the experience gained in the pilot study, the final version of the data 
extraction form (see appendix D) was used to collect the following information: 
Number of fully-screened patients; race or ethnicity; % type II diabetes; % 
prevalence; duration of diabetes; visual acuity; reference standard used; grading 
guideline used; cut-off criteria; index technology (i.e type of camera, resolution); 
field positioning and number of fields; pupil dilation; stereopsis; % unreadable 
images; screen display resolution; image compression. The main outcomes of 
interest were sensitivity and specificity, and outcomes in the form of true positives 
(TP), false positives (FP), true negatives (TN) and false negatives (FN) if available. In 
cases where these values were not available, we derived the numbers from the 
sample size, DR prevalence and reported sensitivity and specificity.26 Data was 
extracted by one reviewer (AC) and relevant predictor and outcome variables 
(sensitivity, specificity, prevalence and 2x2 tables, if available) were confirmed 
independently by a second reviewer (HS). Finally, a 2x2 table was constructed based 
on the data extracted from the studies, defining the patient as the unit of analysis. 
Primary authors were contacted in cases where studies provided insufficient 
information to reconstruct the 2x2 tables. 
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 About half of the articles reported multiple results comparing different tele-
ophthalmology protocols (e.g. more than one estimate of diagnostic accuracy per 
primary study). To avoid clustering effect,27 we used a hierarchical approach to 
choose one comparison per study: (1) protocols using pharmacologic dilation and 
two or more field images per eye (2) protocols without pharmacologic dilation with 
two or more field images per eye (3) protocols with pharmacologic dilation and a 
single field image per eye (4) protocols without pharmacologic dilation and a single 
field image per eye.  
Quality assessment was performed using the revised QUADAS2 (Quality Assessment 
of Diagnostic Accuracy Studies) criteria, which was adapted specifically for this 
review, as suggested by current guidelines (Appendix E).28 No attempt was made to 
assign a score to the QUADAS2 items, as this tool is not intended to generate a 
summary quality score.29,30 Instead, risk of bias of each study was assessed as high, 
low or unclear across the four QUADAS2 domains (patient selection, administration 
of the index test, reference standard and patient flow). 
3.2.5 Data synthesis and statistical analysis  
Categories for analysis 
As planned in the study protocol, we stratified the data into two categories 
according to cut-off criteria. Category 1 included studies that aimed to detect any 
diabetic retinopathy (at least one microaneurysm observed); category 2 included 
studies that aimed to detect referable retinopathy (defined differently across 
studies). Accuracy estimated at multiple test cut-offs was available in many studies; 
in these cases, studies contributed one set of data points per category.  
Meta-analysis 
A meta-analysis was conducted separately for each category using a hierarchical 
bivariate random effects model, proposed by Reitsma et al.31 Instead of using the 
diagnostic odds ratio, the bivariate approach uses sensitivity and specificity pairs as 
the starting point of the analysis, preserving the two-dimensional nature of the 
data.32 Besides accounting for heterogeneity beyond chance, the bivariate model has 
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the advantage of incorporating the negative correlation that may exist between 
sensitivity and specificity, while accounting for variation within and between 
studies.33,34 Summary sensitivity, specificity, positive/negative likelihood ratios 
(LR+;LR -) and diagnostic odds ratio (DOR) were calculated for each category using 
the bivariate method. Likelihood ratios are considered a useful measure for 
clinicians. The LR- indicates how likely a negative test result is in a diseased person 
compared to non-diseased person; conversely, LR+ estimates the frequency of a test 
positive result in diseased compared to non-diseased individuals.35 The DOR is 
calculated by LR+/LR- and it is interpreted as the odds of positivity in diseased versus 
the odds of positivity in non-diseased. Values in DOR range from zero to infinity, 
higher values indicate better discriminatory test performance.36 
To graphically present the results, we plotted the hierarchical SROC (summary 
receiver operating characteristic) graph for each category, which allows the 
visualization of the test performance along different thresholds.37,38  This model 
developed by Rutter and Gatsonis37 also accounts for variation within and between 
studies, due to its hierarchical approach.39 Based on this model, we plotted the 
individual and summary sensitivity and specificity pairs in an ROC graph where the y 
axis indicates the index test’s sensitivity and the x axis equals 1-specificity. For 
category 1 studies, we calculated the AUC (area under the curve) with the 
corresponding 95% confidence region and 95% prediction region.40,41 If the AUC is 
100% then the test discriminates perfectly between diseased and non-diseased 
patients, whereas an AUC of 50% indicates poor diagnostic accuracy.42,43 Given that 
category 2 studies use various thresholds of test positivity, the AUC was not 
calculated.40 
Heterogeneity 
Initially, heterogeneity between studies was visually assessed through paired forest 
plots. Cochran Q (X2 test) and I2 statistics were used to describe study dispersion 
based on sensitivity and specificity estimates of included studies.44,45 Statistical 
significance of Cochran Q test was assumed at a P value less than 0.10, due to the 
power limitations of the test. I2 values of 25% 50% and 75% were considered of low, 
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moderate and high inconsistency, respectively.44  Hierarchical ROC curve was also 
used to assess heterogeneity likely due to threshold effect. With the hierarchical 
SROC plot we were able to assess the proportion of heterogeneity likely due to 
threshold effect. A shoulder-like curve where studies are tangent to the ROC curve 
indicates that the observed variability between studies may be due to a threshold 
effect.46,47  
Finally, potential sources of heterogeneity were explored using subgroup analysis.48 
We defined a priori the following characteristics as potential relevant covariates: 
Pharmacologic dilation (“yes/mixed” or “no”), number of fields captured per eye 
(“single” or “multiple fields”), reference standard used (“7 field ETDRS photographs” 
or “slit-lamp biomicroscopy”), type of diabetes (“type 1” or “type 2” diabetes) and 
risk of patient selection bias according to QUADAS2 criteria (“uncertain/high risk” or 
“low risk”).49 Due to the exploratory nature of covariate analysis and to the small 
number of studies per covariate, a meta-regression was not undertaken for the 
above mentioned covariates.50 
 As a way to evaluate the possible association of up-to-date technologies on the 
diagnostic performance of tele-ophthalmology programs, we executed a random 
effects meta-regression of the DOR as the outcome and year of publication as the 
independent variable.51 Thus, we considered the year of publication as an indicator 
of improvement in both digital photography technologies and learning experience 
associated with tele-ophthalmology. We performed a t-test to assess the null 
hypothesis of no effect of year of publication (i.e recent technologies) on the DOR.52 
A P value <0.05 was considered statistically significant.  
Sensitivity analysis and publication bias 
We repeated the analysis including only studies that fully met QUADAS2 criteria in all 
four domains (patient selection, administration of index test, reference standard and 
patient flow). As a concern for publication bias, we performed a funnel plot based on 
DOR of each study (in logarithm scale) and their respective standard error. Finally, 
we tested for symmetry and small-study effect using a linear regression approach as 
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described by Egger et al.53–55 A P value less than 0.05 was considered statistically 
significant for small study effect.56 This test was also used to numerically estimate 
funnel plot asymmetry. 
Statistical analysis was performed with Stata 12 (Stata Corp, Austin, TX USA). This 
study was supported by a grant from the Ontario Innovation Fund. The founding 
source had no role in the collection, analysis or interpretation of the data. Authors 
have no industry funding source or industry conflict of interest to disclose.  
3.3 Results 
3.3.1 Search results and study characteristics 
After removing duplicates, 1060 citations were initially screened from which 156 
were shortlisted for full text assessment. A total of 22 articles met our criteria for 
review;7,57–78  primary authors from two included studies74,77 were contacted for 
further information from whom only one replied.74 Thus, one article was excluded 
due to lack of sufficient information.77 Finally, one additional study was identified 
through manual search of bibliographies of selected studies, for a total of 23 
included studies for data collection and analysis. Inter-reviewer agreement for study 
inclusion was excellent (Cohen’s k=0.83). The study identification and selection 
process is described in Figure 3.1. 
Characteristics of included studies are outlined in Table 3.1. The 23 studies included 
a total of 5,541 fully screened patients, with a median study size of 149 (IQR 112). 
Patients were mainly male (mean 54.2%), type II diabetic patients (mean 79%) of 
median age 57 years (IQR 10.4 years). The median prevalence of any diabetic 
retinopathy and referable retinopathy was 34.85% (IQR 15.2%), and 31% (IQR 41%) 
respectively. The majority of tele-ophthalmologic protocols used a non-mydriatic 
digital camera (69.6%), captured multiple field images per eye (52%) and used 
pharmacologic mydriasis for pupil dilation (52%). Interestingly, only 44% of studies 
used the recommended gold standard by the American Telehealth Association6 (7 
field ETDRS photographs), whereas the remaining 56% used slit-lamp biomicroscopy 
as the reference standard. Some studies evaluated the effectiveness of the tele-
ophthalmology program at different thresholds, with and without pharmacologic 
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dilation, and used different number of fields captured per eye, thus reporting 
multiple diagnostic accuracy endpoints. The 23 final articles contributed to 31 
sensitivity and specificity pairs in all.  
3.3.2 Quality assessment 
Studies varied in quality (Table 3.2, Figure 3.2). There were nine studies of low risk of 
bias across all four domains of QUADAS2 criteria. Concerns about index technology 
application were uniformly low for all studies in the quality assessment; similarly, all 
studies adequately reported blinding of image readers. The two main issues arising 
were related to the selection of patients and the analysis and/or interpretation 
criteria of the index test. Patient selection was a concern in three studies,70,73,78 
where patients were not enrolled on a consecutive or random basis. In addition, 
three studies7,74,76 did not provide sufficient information to assess risk of patient 
selection bias. Eight studies removed from the diagnostic accuracy analysis those 
patients with uninterpretable results (ie. unreadable images), which may lead to 
overoptimistic diagnostic accuracy outcomes.49  Similarly, some studies did not 
report details about the data analysis, or whether they included or not the full 
spectrum of patients. 
Of note, less than 40% of included studies provided sufficient data about patient 
race/ethnicity, visual acuity measures and image compression. Moreover, only 56% 
of studies specified the type of diabetes. Thus, information regarding these 
covariates was not summarized nor incorporated in the meta-analysis. 
3.3.3 Meta-analysis 
A wide range of results was observed among studies detecting any DR (category 1) 
and referable DR (category 2). Figures 3.3 and 3.4 show individual accuracy 
measures in a paired forest plot for each category. As anticipated in meta-analyses of 
diagnostic accuracy studies,79 pooled results showed considerable heterogeneity 
between included studies, which was statistically significant among both categories 
(X2 P value <0.001). Inconsistency ranged from moderate to high, except for 
sensitivity among studies detecting referable DR, where inconsistency was only 
moderate (I2 71%; 95% CI: 57-86). The meta-analysis summary estimates were 
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obtained using the hierarchical bivariate approach, which is the recommended 
method for synthesis of diagnostic accuracy studies in presence of significant 
heterogeneity.80 However, summary estimates should still be cautiously interpreted 
given the marked heterogeneity amongst studies. 
Synthesis of results by category 
Summary statistics (sensitivity, specificity, DOR, LR(+), LR(-)) and their corresponding 
95% confidence intervals for both categories are outlined in Table 3.3. 
Category 1. Detection of any DR  
This category included all studies that aimed to detect any DR (at least one micro-
aneurysm or worse), which involved 16 studies for a total 3,167 fully screened 
patients. After pooling the sensitivity and specificity of single studies using the 
bivariate method, we obtained a combined sensitivity of 0.89 (95% CI: 0.81-0.93) and 
combined specificity of 0.94 (95% CI: 0.89-0.96). As expected from pooling studies 
with identical cut-off criteria, the proportion of heterogeneity likely due to threshold 
effect was zero.  
The accuracy of tele-ophthalmology for detecting any DR is graphically shown using 
the hierarchical ROC curve that illustrates the summary point and the individual 
study datapoints (Figure 3.5a). Using this approach, we found an AUC of 0.97 (95% 
CI: 0.95-0.98) and a DOR of 113 (95% CI: 51-248). Although 60% of studies are 
located towards the upper left of the graph indicating good test performance, the 
presence of outliers influences the 95% prediction ellipse downwards.   
Category 2. Detection of referable retinopathy 
In this category, all studies that aimed to detect “referable DR” were included. Thus 
we identified 15 studies, including 3,794 fully screened patients. The overall 
sensitivity and specificity was 0.91 (95% CI: 0.87-0.94) and 0.92 (95% CI: 0.88-0.95), 
respectively. According to the hierarchical bivariate model analysis, the proportion of 
heterogeneity likely due to threshold effect was 0.13. However, this category 
incorporates different thresholds which challenge the interpretation of a single 
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paired estimate provided by the bivariate method, as it indicates the performance of 
an unknown average threshold. Moreover, the prevalence of referable DR was 
widely spread among studies (prevalence range: 5% -77%; IQR 41%). Thus, it is more 
adequate to base the analysis on the hierarchical SROC plot that allows assessing the 
performance of the test taking all thresholds into account, and visualize individual 
study results (Figure 3.5b).81 The distribution of the studies in the plot shows a 
greater variability in specificity rather than sensitivity. 
Subgroup analysis 
Results from subgroup analysis are presented in Table 3.4. Due to the limited 
number of studies available in category 1 (detection of any DR), covariance analysis 
of studies that used a single field per eye was not possible. Otherwise, all remaining 
a priori subgroup analyses were conducted. 
Overall, specificity values remained constant across subgroups; sensitivity outcomes 
varied considerably, especially among studies that aimed to detect any DR (category 
1). For example, category 1 studies that used 7 field ETDRS fundus photographs as 
the reference standard showed higher sensitivity (0.96; 95%CI: 0.93-1.00) compared 
to their counterparts that chose slit-lamp biomicroscopy for gold standard 
(0.84;95%CI: 0.76-0.91). Moreover, studies that did not use pharmacologic dilation 
had a lower sensitivity compared to the overall calculated for the detection of any 
DR (0.84 versus 0.89). However, such differences in sensitivity among the above 
mentioned subgroups did not hold for category 2 studies (detection of referable DR). 
Heterogeneity did not significantly improve across subgroups. Nevertheless, studies 
that used 7 field ETDRS photographs as the reference standard were less 
inconsistent compared to the overall estimate.  
Meta-regression results for each category are represented in the bubble plots 
(Figure 3.6). The magnitude of each circle is proportional to the inverse of the 
within-study variance of the corresponding study. Only category 1 studies (detection 
of any DR) showed a statistically significant association between year of publication 
and increased DOR (p-value 0.002).  
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Sensitivity analyses and publication bias 
Publication bias was visually assessed by an individual funnel plot per category 
(Figure 3.7). The funnel plot is noticeably asymmetric among both categories, with 
missing studies at the bottom left of the graph indicating potential publication bias 
towards studies with positive results. For studies that detect any DR, Egger’s test for 
small study effects was non-significant (p-value 0.072), discarding the influence of 
small study effects in the asymmetry of the funnel plot. In contrast, evidence of small 
study effects was found among studies detecting referable retinopathy (p-value 
0.004).  
When sensitivity analyses were performed for category 1 studies, summary 
sensitivity endpoints of individual studies were significantly less heterogeneous 
when studies with high risk of bias were excluded (Cochrane Q 8.79; P value 0.19) 
(see Appendix F). Diagnostic accuracy and heterogeneity remained constant in 
category 2 studies (detection of referable retinopathy). 
3.4 Discussion 
3.4.1 Principal findings 
Considering the quantitative summary results from the present review, it appears 
that tele-ophthalmology approaches meet the requested targets for an effective 
diabetic retinopathy screening program, as recommended by the Canadian 
Ophthalmological Society (sensitivity >0.80, specificity >0.90).22,82 In category 1, 
which included studies with a common threshold value (detection of any DR), 
summary estimates showed a satisfactory diagnostic performance (sensitivity 0.89, 
specificity 0.94). In line with these findings, category 2 studies also showed high 
diagnostic performance for the detection of referable retinopathy (sensitivity 0.91, 
specificity 0.92). Although these are satisfactory outcomes, substantial heterogeneity 
was observed in both categories (Cochrane test P <0.001), limiting both the clinical 
interpretation and applicability of these summary estimates. Moreover, studies in 
category 2 do not share a common cut-off value, as studies reported different 
threshold definitions for the detection of referable DR. In such situation, a summary 
estimate calculated from the bivariate model represents an average operating point 
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for an average unknown threshold, which has no clinical significance.80 The 
interpretation of the hierarchical SROC plot for this category (Figure 3.5) has greater 
importance as it adequately represents study information from different 
thresholds.81  
Exploration of potential sources of heterogeneity is of crucial importance in 
systematic reviews.48,49 Thus, we performed subgroup analyses to identify potential 
sources of variability previously suggested in the literature. This approach also 
provided the appropriate framework to explore the influence of choice of reference 
standard on the diagnostic performance of tele-ophthalmology programs. Among 
category 2, we noted that studies using a single image approach had an inferior 
diagnostic performance (sensitivity 0.82; specificity 0.86) compared to the overall 
analysis (sensitivity 0.91;specificity 0.92) These findings resonate with previous 
studies that used a single field photograph per eye for DR assessment and reported 
sensitivity values as low as 0.71.83 With a single field photograph, pathologies at the 
retinal periphery may be missed, which in turn influences the rate of false negatives 
and affects the sensitivity of the screening test.71,72 
We observed further differences in summary sensitivity endpoints among category 1 
subgroups (Table 3.4). First, we observed that the choice of gold standard had some 
impact on the sensitivity outcomes of the index test. Studies using 7 field ETDRS 
photographs as the gold standard had greater sensitivity (0.96; 95%CI: 0.93-1.00) 
compared to studies that chose ophthalmoscopy (0.84; 95%CI:0.76-0.91). Our finding 
is of special importance, since 54% of included studies reported the use of 
ophthalmoscopy as the reference standard for the evaluation of DR screening 
programs, instead of the recommended gold standard by the American Telehealth 
Association (7 field ETDRS photographs).6 Based on our results, researchers may take 
into account that the choice of ophthalmoscopy over 7 field ETDRS photographs as 
the gold standard may negatively affect the sensitivity performance of the index test 
if it aims to detect early forms of DR.  
Second, meta-regression analysis found that recently published studies were 
associated with greater diagnostic accuracy for the detection of any DR. Such a trend 
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could be related to the continuous improvement of digital technologies that 
facilitate the identification of subtle manifestations of DR such as micro-aneurysms. 
Finally in the sensitivity analysis, we found that poor methodological quality also 
accounts for some observed heterogeneity in pooled sensitivity results among 
category 1 studies. After excluding studies with risk of bias as graded using QUADAS2 
criteria, we found that heterogeneity of sensitivity estimates was no longer 
significant (Cochran Q 8.79; P value 0.19), and inconsistency among studies was 
reduced to 31.7% (moderate inconsistency). However, such difference was observed 
only in sensitivity estimates of studies in category 1 and did not hold for studies in 
category 2 (referable retinopathy).    
It is important to note that in all screening programs there is certain degree of harm. 
In the case of tele-ophthalmology, the potential harm related to the screening 
process itself is generally innocuous. If dilation drops are used, there is a small risk 
for temporal development of open angle glaucoma. However, the risk of this adverse 
event is very low, 1 in 20,000 cases.87  
Adverse effects of screening are also related to the occurrence of false positive or 
false negative results. Patients with false positive tests undergo additional 
unnecessary examinations such as ocular coherence tomography or fluorescein 
angiography.12 Besides the psychological distress resulting from positive results, 
confirmatory tests do not represent significant harm. Allergic reactions may occur 
due to administration of sodium fluorescein during fluorescein angiography, 
although serious complications are rare.88 False negative tests may translate to 
missed opportunities for preventing severe vision loss.  
According to our results, tele-ophthalmology screening for DR can accomplish 
sensitivity and specificity estimates over 80% and 95%, respectively. Such diagnostic 
performance is considered sufficient for supporting the early diagnosis of DR through 
screening programs.88    
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3.4.2 Strengths and limitations 
To our knowledge, this is the first meta-analysis that evaluates and summarizes the 
diagnostic performance of tele-ophthalmology screening for the assessment of DR. 
This meta-analysis has a number of strengths. We performed a robust literature 
search in collaboration with an information specialist, which included a 
comprehensive search of major scientific databases and reference lists of reviews 
and articles. In addition, we selected studies according to strict inclusion criteria 
assessed by two reviewers; we also assessed methodological quality of studies and 
used two suitable statistical models for diagnostic meta-analysis in the presence of 
heterogeneity and different thresholds.   
There are some limitations to be considered when interpreting the study results. We 
observed considerable heterogeneity among both study categories (Cochran Q P 
value <0.001), which could be explained in part by threshold effect (for category 2 
studies) and poor methodological quality of some studies (for category 1 studies). 
According to our exploratory subgroup analysis, differences in the selection of 
reference standard and number of fields taken per eye may also contribute for the 
heterogeneity observed. However, subgroup analyses did not fully explained the 
variability found, as results remained heterogeneous even after stratifying by pre-
defined covariates. Thus, in presence of substantial heterogeneity summary results 
should be cautiously interpreted. Evidence of publication bias is also a concern when 
interpreting summary results, as it might have an impact on study conclusions 
leading to overoptimistic results. However, it has been debated that in the context of 
reviews of diagnostic accuracy studies applying such tests for funnel plot asymmetry 
often lead to a high type two error rate (publication bias is incorrectly indicated by 
the test).84  
This meta-analysis was also limited by lack of information provided in primary 
studies. We observed that almost 45% of authors did not report important 
population characteristics such as ethnicity, type of diabetes and diabetes duration. 
Reporting of visual acuity was almost non-existent, as only three authors reported 
visual acuity of their study population.64,69,70 Lack of information on visual acuity 
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precludes any estimation of relationships between diagnostic accuracy and 
functional status. Similarly, some index test characteristics were also poorly 
reported. For example, 65% of studies did not mention the digital image resolution 
and 80% of studies did not provide information about image compression or image 
formatting. These are index technology characteristics of important relevance in 
image quality, which may influence the correct identification of DR cases.85,86 
Because of the limited information provided on population and digital image 
characteristics, future reporting of these research studies should give greater 
attention to provide more complete information about population characteristics, 
and detailed description of index technology devices. This will allow future reviews 
to account for these important sources of variability. 
In conclusion, this systematic review with meta-analysis suggests that tele-
ophthalmology tests used to assess any DR and referable DR yield satisfactory 
sensitivity and high specificity. Of note, diagnostic accuracy estimates amongst 
individual studies were highly variable, compromising the clinical significance of the 
meta-analysis results which in turn should be cautiously interpreted.  
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3.6  Tables and figures 
 
 
Figure 3.1 PRISMA flow diagram of study selection (systematic review) 
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Table 3.1. Characteristics of primary studies included in the Meta-analysis 
 
Citation Country N (fully-screened) 
Mean 
age 
(years) 
Male (%) 
Type II 
diabetes 
(%) 
Gold standard Cut-off criteria 
DR 
prevalence 
Ahmed J., et al (2006) United States 156 60 54.5% 97.9% Ophthalmoscopy Any DR 15.8%* 
Aptel F., et al (2008) France 79 52.4 0.89 (men/women) 62% Ophthalmoscopy Any DR 25.3% 
Baeza M., et al 
(2004)+ Spain 188 68.5 34.7% 100% Ophthalmoscopy 
Any DR 41.25% 
Referable 
DR 
14.3% 
Baeza M., et al 
(2009)+ Spain 216 68.5 43.7% 90% 
7 field ETDRS 
photographs 
Any DR 37.2%* 
Referable 
DR 14.3% 
Boucher MC., et al 
(2003) Canada 79 59.9 49% NR 
7 field ETDRS 
photographs 
Any DR 63.30% 
Referable 
DR 53.10% 
Chun DW., et al 
(2007) United States 120 NR 50.8% NR Ophthalmoscopy Any DR 32.5%* 
Hansen AB., et al 
(2004) Denmark 83 47 60.2% 27.0% 
7 field ETDRS 
photographs 
Referable 
DR 74.7%* 
Herbert HM., et al 
(2003) United Kingdom 145 NR NR 73% Ophthalmoscopy Any DR 26.0% 
Li HK., et al (2010) United States 76 59.4 37.6% NR 7 field ETDRS photographs 
Any DR 82.9% 
Referable 
DR 77.6%* 
Lin DY., et al (2002) United States 197 NR 58.0% NR 7 field ETDRS Referable 36.6%* 
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photographs DR 
Lopez-Bastida J., et al 
(2007) Spain 651 50.8 51.8% NR Ophthalmoscopy Any DR 42.5% 
Maberley D., et al 
(2002) Canada 100 54.6 31.0% NR Ophthalmoscopy 
Any DR 40.0% 
Referable 
DR 31.0%* 
Massin P., et al (2003) France 74 52 62.2% 85.13% 7 field ETDRS photographs 
Referable 
DR 12.9%* 
Molina-Fernandez E., 
et al (2008) Spain 49 65.4 NR 100% Ophthalmoscopy Any DR 28.7% 
Murgatroyd H., et al 
(2004) United States 293 
63 
(median) 
57% 65% Ophthalmoscopy 
Any DR 37.8% 
Referable 
DR 4.70% 
Olson JA., et al (2003) United Kingdom 550 56.5 65% 82.1% Ophthalmoscopy 
Any DR 27.27% 
Referable 
DR 9.9% 
Phiri R., et al (2006) Australia 149 68.5 57% NR 7 field ETDRS photographs 
Referable 
DR 48.6%* 
Robbins AS., et al 
(2001) United States 152 NR NR NR Ophthalmoscopy Any DR 18.0% 
Rudnisky CJ., et al 
(2007) Canada 102 59.9 65.7% 86.3% 
7 field ETDRS 
photographs 
Referable 
DR 4.9% 
Scanlon PH., et al 
(2003) United Kingdom 1542 65 NR NR Ophthalmoscopy 
Referable 
DR 11.6% 
Schiffman RM., et al 
(2005) United States 94 57 41% NR 
7 field ETDRS 
photographs 
Any DR 76.10% 
Referable 
DR 67.02%* 
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Ting DS., et al (2012) Australia 136 53.9 NR 71% Ophthalmoscopy Any DR 31.3% 
Vujosevic S., et al 
(2009) Italy 55 57.1 60% 67.3% 
7 field ETDRS 
photographs 
Referable 
DR 51.4% 
* Prevalence calculated from reported 2x2 tables    DR= Diabetic retinopathy      NR= Not reported   
Ophthalmoscopy examination included slit-lamp biomicroscopy performed by experienced ophthalmologist or retina specialist 
+Studies may contain overlapping patient populations 
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Table 3.2 QUADAS2 assessment results 
Citation, year PATIENT SELECTION 
INDEX 
TEST 
REFERENCE 
STANDARD 
FLOW AND 
TIMING 
Ahmed J., et al (2006) Low Low Low High 
Aptel F., et al (2008) Low High Low Low 
Baeza M., et al (2004) Low Low Low Low 
Baeza M., et al (2009) Low Low Low Low 
Boucher MC., et al (2003) Low Low Low Low 
Chun DW., et al (2007) Low Low Low High 
Hansen AB., et al (2004) High Low Low Low 
Herbert HM., et al (2003) Unclear Low Low Low 
Li HK., et al (2010) High Low Low Low 
Lin DY., et al (2002) Low Low Low Unclear 
Lopez-Bastida J., et al (2007) Low Low Low Low 
Maberley D., et al (2002) Low Low Low Low 
Massin P., et al (2003) Low Low Low Unclear 
Molina-Fernandez E., et al (2008) Low Low Low Low 
Murgatroyd H., et al (2004) Low Low Low High 
Olson JA., et al (2003) Unclear Low Low Low 
Phiri R., et al (2006) Low Low Low Low 
Robbins AS., et al (2001) Low Unclear Low High 
Rudnisky CJ., et al (2007) Low Low Low Low 
Scanlon PH., et al (2003) Low Low Low Unclear 
Schiffman RM., et al (2005) High Low Low Low 
Ting DS., et al (2012) Low Low Low Low 
Vujosevic S., et al (2009) Unclear Unclear Low Low 
 
Figure 3.2 QUADAS2 assessment (risk of bias by domain) 
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  Figure 3.3. Paired forest plot of meta analyses of studies included in category 1 
(detection of any DR) 
Figure 3.4. Paired forest plot of meta-analyses of studies included in category 2 
(detection of referable DR) 
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Figure 3.5 Hierarchical SROC (summary receiver operator characteristic) plots for 
detection of any diabetic retinopathy (5a), and detection of referable diabetic 
retinopathy (5b)   
 
Table 3.3  Meta-analysis summary results per category (detection of any diabetic retinopathy and 
detection of referable diabetic retinopathy) 
    Heterogeneity   Diagnostic performance 
Category Cut-off Inconsistency (I2) [95% CI] 
Cochran Q 
(Chi2 P value)   
Sensitivity 
[95% CI] 
Specificity 
[95% CI] 
DOR 
[95%CI] 
LR +          
[95% CI] 
LR -            
[95% CI] 
Category 
1                   
(n=16) 
Any DR 96.95%          [94-99] 
56.3                         
(P <0.001)  
0.89       
[0.81-0.93] 
0.94        
[0.89-0.96] 
113            
[51-249] 
13.8           
[8.3-22.7] 
0.12            
[0.07-0.21] 
Category 
2                 
(n=15) 
Referable 
DR 
81.95%         
[60-100] 
10.7                      
(P 0.002)  
0.91       
[0.87-0.94] 
0.92        
[0.88-0.95] 
121            
[58-253] 
12.0              
[7.1-20.1] 
0.10              
[0.07-0.14] 
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Figure 5b. Referable Diabetic Retinopathy
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Table 3.4. Subgroup analyses of potentially relevant covariates to explore heterogeneity 
 
  
Number 
of 
 Heterogeneity 
  Sensitivity 
 Specificity  
 studies 
 Inconsistency 
(I2) 
Cochrane Q 
(Chi2) 
 (95% CI)  (95% CI)  
Detection of any diabetic retinopathy 
Overall analysis 16 
          97%  
        (94-99) 
56.3  
(<0.001) 
 0.89    
 (0.81-0.93) 
 
0.94    
(0.89-0.96) 
 Pharmacologic dilation 
Yes/mixed 11          92%          (82-100) 
22.3  
(<0.001) 
 0.91    
 (0.82-0.95)  
0.95 
(0.92-0.97)  
No 4          94%           (88-99) 
30.4  
(<0.001) 
 0.84    (0.66-
0.93)  
0.91   
(0.68-0.98)  
Number of fields 
Multiple 13 
        56%  
          (0-100) 
4.5  
(0.052) 
 0.91   (0.88-0.95) 
 
0.93 
(0.90-0.97)  
Single* 3       - -  -  -  
Gold standard 
7-field ETDRS photographs 4 
          72%  
           (37-100) 
6.99  
(0.015) 
 0.96     
(0.93-1.00)  
0.93 
(0.86-1.00)  
Slit-lamp biomicroscopy 12 
           97%  
            (93-99) 
50.65  
(<0.001) 
 0.84     
(0.76-0.91)  
0.94   
(0.90-0.97)  
Risk of patient selection bias 
Low risk 12 
           90%  
            (79-100) 
19.3  
(<0.001) 
 0.88 
(0.82-0.95)  
0.94 
(0.89-0.97)  
Uncertain/High risk 4 
            95%  
         (90-99) 
38.3  
(<0.001) 
 0.92     
(0.57-0.99)  
0.94 
(0.78-0.98)  
Detection of referable diabetic retinopathy 
Overall analysis 15                  82% 10.7   0.91    
 
0.92    
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             (60-100) (0.002) (0.87-0.94) (0.88-0.95) 
Pharmacologic dilation 
Yes/mixed 8 
 74%  
(42-100) 
7.6  
(0.011) 
 0.92 
 (0.88-0.95)  
0.95 
(0.88-0.98)  
no 7 
 60%  
(10-100) 
5.0  
(0.041) 
 0.87   
(0.82-0.93)  
0.89   
(0.82-0.96)  
Number of fields 
Multiple 11 
 72%  
(38-100) 
7.2  
(0.014) 
 0.93  
 (0.89-0.95)  
0.94 
(0.89-0.97)  
Single 4 
 79%  
(95-100) 
9.5  
(0.004) 
 0.82  
(0.74-0.88)  
0.86    
(0.75-0.93)  
Gold standard 
7-field ETDRS photographs 10 
 69%  
(29-100) 
6.29 
 (0.022) 
 0.92   
(0.88-0.95)  
0.93 
(0.88-0.97)  
Slit-lamp biomicroscopy 5 
 77%  
(47-100) 
8.23  
(0.008) 
 0.89   
(0.84-0.95)  
0.92    
(0.86-0.98)  
Risk of patient selection bias 
Low risk 10 
 84%  
(65-100) 
12.2  
(0.001) 
 0.88   
(0.84-0.92)  
0.93 
(0.87-0.97)  
Uncertain/High risk 5 
 0%  
(0-100) 
0.004  
(0.499) 
 0.94  
 (0.90-0.96)  
0.88    
(0.85-0.90)  
* Covariate analysis could not be conducted for this subgroup given the small number of studies (n <4)  
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Figure 3.6   Meta-regression of log diagnostic odds ratio (DOR) on year of study 
(independent variable) for A. Detection of any diabetic retinopathy and B. Detection of 
referable diabetic retinopathy 
 
 
 
 
 
 
 
 
 
 
Figure 3.7 Funnel plot of standard error of log diagnostic odds ratio (logDOR) by logDOR 
for each study category to illustrate possible publication bias. Egger’s p-value < 0.05 
indicates presence of small study effects 
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4.1  Introduction 
Diabetic retinopathy (DR) is a sight threatening complication in patients with diabetes 
mellitus,  and is usually asymptomatic in early stages1–3. According to recent 
investigations, 2.5% of diabetic patients worldwide suffer severe vision loss derived 
from DR, being this the leading cause of blindness among working-aged individuals.4,5 
Regular eye examination is fundamental to detect DR progression and to promote 
timely therapeutic interventions.6 Laser photocoagulation for example,  is an effective 
treatment  for  DR with 52% of patients experiencing reduction of severe vision loss if 
they receive treatment after timely diagnosis of sight-threatening DR.7,8  
Unfortunately, less than 50% of diabetic patients follow the eye examination guidelines 
by the American Academy of Ophthalmology9, resulting in lost opportunities to prevent 
severe vision loss by means of adequate treatment delivery.5,10,11 Besides non-
modifiable factors, limited availability of eye care specialists, travelling difficulties and 
time constraints are also well-known reasons for non-adherence in non-urban areas.12–
15  
Within this context, pharmacy-based tele-ophthalmology has emerged as a possible 
alternative that may facilitate compliance with evidence-based recommendations and 
reduce barriers to specialized eye care.16–18 In this program, retinal digital images are 
captured in a local pharmacy and securely transmitted electronically to a specialized 
reading centre, where photographs are graded by an eye specialist.19 Patients with signs 
of DR can then be referred to an eye-care professional for comprehensive assessment.20 
Thus, the workload of routine eye examination is transferred to other (presumably less 
expensive) settings, optimizing the use of specialized eye-care services. In addition, this 
approach eliminates unnecessary traveling for patients and eye care professionals, and 
it may improve the consistency of community-based eye care delivery without 
geographic constraints.17,21 
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Cost-effectiveness of new technologies should be explored before implementation in 
specific settings in order to facilitate estimation of the eventual costs of introducing new 
technologies, as well as their potential benefits compared with competing 
alternatives.22 Amongst cost-effectiveness studies conducted in the DR screening arena, 
few have evaluated tele-ophthalmology as an alternative for in-person examination.23–27 
Thus, the objective of this study was to estimate the cost-effectiveness of mobile tele-
ophthalmology screening compared to primary care examination for the diabetic 
population residing in non-urban areas of Southwestern Ontario (Canada). Our primary 
interest was to assess the additional cost per case detected of any diabetic retinopathy 
with pharmacy-based tele-ophthalmology on an annual basis from the health system 
perspective. Unlike previous studies, we consider a more realistic scenario in which the 
tele-ophthalmology program would not entirely replace in-person examination, while 
also accounting for the effects of performing a dilated or non-dilated examination with 
tele-ophthalmology. 
4.2 Methods 
4.2.1 Study setting 
The economic analysis was designed for the South-western Ontario context, specifically 
non-urban areas at the Erie-St. Clair Local Health Integration Network (LHIN).28 Such 
non-urban areas have limited specialized eye-care and diabetic care, in which a 
pharmacy-based tele-ophthalmology system may be of benefit, as it would help 
reaching diabetic individuals who otherwise would not get an eye examination.29 As of 
2011, the census subdivision contemplated in this study (Chatham-Kent) reported a 
total of 103,671 habitants (population density of 14.2 people per km2), from which 
10,354 are type I or type II diabetic persons over 20 years old.30,31 An explicitly urban 
model (ie Toronto) was not chosen based on the assumption that in-person exams 
would be relatively easy to access in this setting. An explicitly rural model (Canada’s far 
north) was not chosen since tele-ophthalmology may be the only alternative in such 
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locations. However, there is true equipoise in understanding the cost-effectiveness of 
this program in a context such as the Erie-St Clair LHIN. 
4.2.2 Decision-tree model and study interventions 
A decision-tree was elaborated using TreeAge Pro Suite 2013 (TreeAge Software, Inc, 
Williamstown, Massachusetts), to compare primary care examination (comparator 
program) versus pharmacy-based tele-ophthalmology (intervention program). 32 A 
simplified diagram of the decision-tree is provided in Figure 4.1 (for the full model, refer 
to appendix G). In the analytical framework, we assumed that the pharmacy-based tele-
ophthalmology program coexisted along with the reference program, increasing the 
volume of DR examinations (Figure 4.1, arm 2) but did not entirely replace in-person 
examination. This assumption aligns to the purpose of the tele-ophthalmology program 
to complement existing eye-care services.  
The model was tailored for a mixed cohort of adults with type I or type II diabetes. The 
outcome of interest was the detection of any diabetic retinopathy, manifested by at 
least one micro-aneurysm (ETDRS ≥ 20).33 This health outcome was chosen based on the 
goal of identifying both early and advanced stages of DR, which would promote an 
appropriate follow-up or timely treatment, if necessary. 
Our interest focused on the potential ability of pharmacy-based tele-ophthalmology to 
strengthen diabetic retinopathy screening coverage at a reasonable cost. Thus, our 
analysis was restricted to the correct detection of DR cases, as opposed to incorporating 
treatment effects and disease progression into the model. A heath care system 
perspective was adopted, where consequences and direct costs pertaining to each 
program were included based on a 12-month time frame. 
Intervention: Pharmacy-based tele-ophthalmology 
The economic model was designed for the evaluation of a category 1 tele-
ophthalmology screening program, used to identify patients with no (or minimal) DR 
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and patients with more than minimal DR.16 We considered the introduction of a part-
time mobile retinal unit, operating on a rotational basis among regional pharmacies at 
the main municipalities of Chatham-Kent. In this model, clinical history and 45 degree 
digital photographs were taken from each eye by an ophthalmic photographer and 
pharmacologic dilation with tropicamide or phenilephrine was optional. Readable digital 
images were sent via electronic communications to the reading center at St. Joseph’s 
hospital in London (ON) for assessment by a retina specialist. Patients with positive 
findings were referred to a retina specialist for a diagnostic confirmation with 
angiography and optical coherence tomography. Similarly, patients with unclear fundus 
photographs were referred to in-person examination with the retina specialist for 
further assessment. 
Comparator: In-person examination (primary care) 
The primary care screening was defined as a dilated fundus examination performed by a 
primary care eye specialist (either an optometrist or ophthalmologist). Patients with 
positive results were referred to a retina specialist for a comprehensive eye examination 
with angiography and optical coherence tomography.  
4.2.3 Identification and calculation of model probabilities 
Probabilities used in the base-case model are shown in Table 4.1. Prevalence of any DR 
(22.5%) was calculated using public reports by the Public Health Agency of Canada and 
the National Coalition for Vision Health.34,35 Screening rate with the reference program 
in Arm 1 (P(ref)) was considered to be identical to the eye examination rate after 
diagnosis of diabetes in Ontario (51.1%).36 After the introduction of the new screening 
intervention (appendix G, Arm 2), the patient had two screening alternatives (in-person 
examination or telescreening) and would choose according to preference for one or the 
other. The option of no screening was also included in both arms of the model. Hence, 
to calculate the screening rate of tele-ophthalmology examinations (P(tele)), we used the 
following formula that considered the increased screening compliance after the 
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introduction of tele-ophthalmology (V) and the proportion of screening examinations 
with tele-ophthalmology based on screening preference (T), as follows      
                             P(tele)= T ( P(ref) х V )   , V ≥ 1, P(tele) <1                                          (1)                 
In this equation, “P(ref) х V” is the overall screening rate for Arm 2, and “P(tele)”  is the 
proportion of those examinations from Arm 2 that correspond to tele-ophthalmology 
screening.  
Both patients’ preferences (T) and screening compliance after tele-ophthalmology (V) 
were derived from published literature. For this purpose, a structured literature search 
was performed among Medline and EMBASE databases using the subject headings 
“telemedicine”, “mobile health units”, “mass screening”, “early diagnosis”, “community 
pharmacy service” (appendix H). Priority was given to studies from primary care 
screening services using mobile screening units in urban or semi-urban settings. For the 
base-case model, the volume increase in DR examinations after tele-screening (V) was 
set to 10%, with 40% of patients favoring pharmacy-based telescreening examination 
over the comparator.18,37,38 Hence, the base-case screening probability for the tele-
ophthalmology arm (Figure 4.1, Arm 2) was 0.562. For detailed calculations of model 
probabilities, refer to appendix I. 
Estimates of the diagnostic performance of tele-ophthalmology were obtained from a 
recent meta-analysis39 that separately reported the summary results according to 
diagnostic threshold. Therefore, we used the summary sensitivity and specificity 
corresponding to the assessment of any DR, and derived the diagnostic performance of 
in-person examination from one of the included studies.40 We also used this data to 
calculate the proportion of unreadable images with tele-ophthalmology with and 
without pharmacologic dilation. Finally, the proportion of dilated examinations was 
obtained from a study that used pharmacy-based tele-ophthalmology for DR screening 
across Canadian provinces.41 It was assumed that pupil dilation with tropicamide or 
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phenylephrine was performed by the pharmacist at the patient’s discretion. All 
probabilities used in the economic model are outlined in appendix J     
4.2.4 Identification and calculation of model costs 
Data sources for estimates of costs included published literature, market prices, 
vendor’s quotations, official government reports and administrative information from 
St. Joseph’s Healthcare in London (ON). Only direct costs were incorporated into the 
model and presented in 2013 Canadian dollars. 
Cost information is provided in Table 4.2. Equipment for the tele-ophthalmology 
program consisted of a non-mydriatic digital fundus camera, a carrying case, an 
adjustable table, a laptop and reading software. Costs related to equipment and 
maintenance were obtained directly from the vendor and was given a 5 year life 
(written communication, 2013). Capital costs were annualized at a 5% discount rate per 
year, corresponding to the rate for Ontario government bonds.42 In contrast, capital 
costs for in-person examination were not included, as the ophthalmoscope and lens are 
already bought and routinely used for any eye examination.  
Traveling costs of the mobile retinal unit consisted on van rental cost (including 
insurance) and fuel expenses for traveling across the Chatham-Kent municipality. Rental 
costs estimates were provided from the vendor; fuel costs were obtained from the 
Ontario Ministry of Energy report and reflected the cost per gallon in Ontario.43 
Pharmacy overhead costs were calculated from the annual Pharmacy Trends Reports, 
which provided information on annual operating expenses per square foot among 
Canadian pharmacies.44 Thus, we adjusted the cost to the part-time use of pharmacy 
space in 2013 Canadian dollars. 
Technician costs for tele-ophthalmology were based on current prevailing wages 
provided by administrators at St. Joseph’s Hospital in London (written communication, 
2013). To estimate the labor cost per patient assessment, a structured literature search 
was conducted with Medline and EMBASE to find economic studies on DR screening 
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that reported information on average minutes of labor cost per patient. Subject 
headings included “diabetic retinopathy”, “diagnostic imaging”, “cost allocation”, 
“healthcare costs” (appendix K). Six studies calculated the average minutes spent by 
personnel for taking and/or assessing eye photographs, which varied between 5 and 15 
minutes.24,45–49 Based on this information, we extrapolated the cost per hour of 
technician labour to the cost per patient assessment with the tele-ophthalmology 
program. 
In-person consultation fees for major eye examination were obtained from the Schedule 
of Benefits of Physician Services by the Ontario Ministry of Health and Long-term care.50 
The ophthalmic reader fee was based on the tele-consultation fee provided by the 
Alberta Healthcare Insurance Plan for pediatricians and related subspecialties.51 It was 
assumed that an Ontario tele-consultation fee for DR assessment would resemble that 
of Alberta for tele-consultation in pediatric specialties. Patient referral costs and 
consumables costs were obtained from vendors’ quotations and administrative 
information from St. Joseph’s Health Care  (London, ON).  
4.2.5 Cost-effectiveness evaluation and sensitivity analysis 
Two measures of effectiveness were analyzed in this study; (1) cases of any DR detected 
(true positives) and (2) cases correctly diagnosed (including true positives and true 
negatives). A case of DR was defined as any DR beyond very mild non-proliferative DR, 
corresponding to a Modified Airlie House Classification ≥20 on the reference standard.33 
Cost- effectiveness was calculated as total cost divided by number of cases detected (or 
number of cases correctly diagnosed). Thus, the Incremental Cost Effectiveness Ratio 
(ICER) was calculated as the extra cost needed to generate (1) an additional case of DR 
or (2) an additional case correctly diagnosed after the implementation of pharmacy-
based tele-ophthalmology.52  
Deterministic Sensitivity Analysis 
92 
 
 
Parameters considered as potential drivers of the model were included in sensitivity 
analysis,   and were assigned plausible ranges based on 95% confidence intervals or 
upper and lower 25% limits around the base-case value. For simplicity we limited the 
reporting of sensitivity analyses to the cost per case detected per year. 
 One way sensitivity analyses were conducted for most data elements to investigate the 
extent to which each variable’s uncertainty affected the model results. Variables 
considered for one-way sensitivity analysis with their respective ranges are listed in 
Table 4.1 (model probabilities) and Table 4.3 (model costs). A multi-way sensitivity 
analysis was also performed, where model parameters were varied simultaneously to 
generate extreme scenarios.  
4.3 Results 
4.3.1 Base-case analysis 
In the base-case analysis we considered a tele-ophthalmology program that achieved a 
10% volume increase in patient compliance, with a 0.18 probability of unreadable 
images and pharmacologic dilation in 33% of examinations. Considering a population of 
10,354 diabetic patients, the tele-ophthalmology program would correctly detect 
additional 136 cases compared to in-person examination only (Table 4.4). Cost-
effectiveness was assessed as (1) cost per case detected, and (2) cost per case correctly 
diagnosed. For (1) the cost-effectiveness of in-person examination and tele-
ophthalmology was $510 and $478.3, respectively, whereas for (2) was $107 for in-
person examination and $73.2 for tele-ophthalmology. The incremental cost-
effectiveness (ICER) was $314.1 per additional case detected and $102 per additional 
case correctly diagnosed (Table 4.5). In both instances the programs were non-
dominant; hence, tele-ophthalmology was always more costly, but more effective than 
in-person examination. (Figure 4.2). 
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4.3.2 Sensitivity analyses 
Sensitivity analyses assessed uncertainties of model parameters, including diagnostic 
accuracy, DR prevalence, compliance and costs. Results of multiple one-way sensitivity 
analyses are outlined in Table 4.6.  We found that the model was stable with regards to 
sensitivity, specificity and prevalence variations. Similar to a previous study,53 workforce 
wages played a significant role in the cost-effectiveness of both screening programs. In 
the case of tele-ophthalmology, we observed that the ICER doubled its base-case value 
when the image reader’s fee (retina specialist) increased from $31.6 to $55.4 per 
patient. This parameter is an important source of uncertainty since Ontario currently 
does not have a tele-ophthalmology code that could serve as a reference for the model. 
For the base-case scenario we used a proxy code from the Alberta Schedule of Medical 
Benefits (code 03.05JJ).54 This code is used by pediatricians (including subspecialties) if 
they provided a five minute evaluation or consultation by telephone or other 
telecommunication methods, which is similar to the service a retina specialist would 
provide in a category 1 tele-ophthalmology program.  
Conversely, if the in-person examination fee increased from $51.1 to $78 per person, 
tele-ophthalmology program dominated at a cost of $603 per true positive case 
detected compared to $737 per case detected with in-person examination.    
Other influential variables in the tele-ophthalmology program included the proportion 
of unreadable images (without pupil dilation) and the grader fee. When the proportion 
of unreadable images increased to 0.43, the ICER also increased to $411.2 per additional 
case detected per year. Similarly, when the tele-ophthalmology grader fee per patient 
incremented up to 25%, the ICER also increased to $633.9 per additional case detected 
per year.   
A two-way sensitivity analysis was conducted to estimate the joint influence of 
screening volume and patients’ preferences on the cost-effectiveness of pharmacy-
based tele-ophthalmology. As expressed in equation (1), both parameters were used to 
calculate the screening rate for both programs under the assumption that the two 
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screening alternatives were available to the patients after the introduction of tele-
ophthalmology (Arm 2). We defined a tele-ophthalmology preference range from 10% 
to 100% and considered a volume increase of 10% (base-case) 15% and 20%. Tele-
ophthalmology remained non-dominant in all combinations (Figure 4.3). Of note, the 
lowest ICER was achieved when all screened patients used pharmacy-based tele-
ophthalmology ($192 per additional case detected per year).  
In the extreme scenario analyses, both costs and probabilities were manipulated to 
generate alternative settings that would represent the best and the worst scenario for 
the introduction of pharmacy-based tele-ophthalmology. In the best-case scenario, 
influential parameters were defined as follows: patient preference for tele-screening 
increased to 0.70 (assuming all patients had a dilated examination), tele-screening 
diagnostic performance was defined according to upper 95% confidence intervals for 
sensitivity and specificity (Se 91%, Sp 97%), while in-person examination was set to its 
lowest diagnostic performance (Se 67% Sp 79%). Also, the rate of unreadable images for 
tele-ophthalmology was fixed at its lowest value (3.3%). Finally, fees corresponding to 
the tele-ophthalmology coordinator, ophthalmic photographer and the retina expert 
grading were reduced by 15% ($20.5, $20.5 and $23.75 respectively). We found that 
tele-ophthalmology dominated at $367.6 per case detected per year, being less costly 
and more effective than in-person examination ($575.1 per case detected per year).   
Alternatively, the worst case scenario was fixed under the poorest diagnostic 
performance for tele-screening (Se 76%; Sp 90%) and the best sensitivity and specificity 
values for in-person examination (Se 83%; Sp 86%), the highest rate of unreadable 
images (43.5%) and a 15% increase in the coordinator, eye photographer and retina 
expert fee ($34.21, $34.21 and $55.21, respectively). In this scenario, tele-
ophthalmology remained undominated although the incremental cost-effectiveness was 
four times higher than the base-case ($1,393 per additional case detected per year).  
95 
 
 
4.4 Discussion 
4.4.1 Cost-effectiveness of tele-ophthalmology 
The detection of DR by means of tele-ophthalmology programs has proven to be a cost-
effective alternative amongst isolated communities, generating savings through lower 
transportation and personnel costs.17,25 In terms of total annual costs, the introduction 
of tele-ophthalmology was more expensive than in-person examination but detected 
15% more cases of any DR at $314.1 per additional case. In the Chatham-Kent context, 
this was translated to 528 more patients attending eye examination, and 136 additional 
DR cases detected.  
A previous study assessed the cost-effectiveness of systematic photographic screening 
versus opportunistic eye examination in the UK.46 Adjusted to 2013 Canadian dollars, 
the incremental cost per additional DR case detected was $83, which was regarded as 
cost-effective within the British healthcare system. In comparison, the incremental cost-
effectiveness of tele-ophthalmology may be too high to consider its implementation in a 
semi-urban context. However, if an exclusive use of tele-ophthalmology is assumed, the 
ICER would be reduced to $192 per case detected, almost half of the base-case value 
and closer to the acceptable cost-effectiveness estimate reported by James and 
colleagues.46  
4.4.2 Sensitivity analyses 
Sensitivity analyses showed an important influence of healthcare specialists’ fees for in-
person examination and interpretation of retinal images. As expected, the ICER 
increased as the fee of retinal image readers increased up to 15% its base-case value. 
Alternatively, when in-person examination cost reached $78 per patient, tele-
ophthalmology became less costly and more effective, dominating over in-person 
examination.  
Undilated tele-screening examinations showed a higher rate of unreadable images, 
which affected the incremental cost-effectiveness of the program. Although pupil 
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dilation may improve image quality and lower the costs, it may prevent patients for 
getting screened at the pharmacy, as reported in previous studies.41,55 Hence, the option 
of including pharmacologic dilation will depend on the overall goal of the tele-
ophthalmology program.16 For example, if the primary concern is to assess more 
patients, then a program without pharmacologic dilation would be convenient, at the 
expense of increasing the proportion of unreadable images.  
4.4.3 Comparison to previous evidence 
In contrast to our findings, other studies have reported tele-ophthalmology to be highly 
cost-effective or even dominant at the base-case analysis.24,56,57 However, comparisons 
of our results with prior published studies are not straightforward due to differences in 
effectiveness outcomes and model assumptions. For instance, Whited and collaborators 
used data from three US agencies to build nine economic models based on the Joslin 
Vision tele-ophthalmology system.24 Tele-ophthalmology dominated clinic-based 
ophthalmoscopy in seven models, and was cost-effective at extra $1,618 (2004 US 
dollars) per additional case treated in the remaining two models. In contrast to our 
model, this study assumed an exclusive initial use of the tele-ophthalmology alternative, 
and its diabetic population was eight to twenty times bigger than in Chatham-Kent, 
assuring maximum efficiency of both labor and equipment.  
In the Canadian context, Maberley et al.,25 evaluated the introduction of a tele-
ophthalmology system in a First Nations community, where retina specialists traveled 
twice a year to make eye-examinations. Similarly, Aoki et al., assessed the introduction 
of a tele-ophthalmology program in a remote US prison versus current practice 
consisting on sporadic eye examinations by eye specialists.56 Both studies assessed the 
cost-effectiveness of an alternative tele-ophthalmology program in terms of quality-
adjusted life-years (QALY), and found tele-ophthalmology to be dominant over current 
practice.25,56 The context in which these studies were framed differs greatly from the 
semi-urban scenario used in our model, as they assumed an exclusive use of the tele-
ophthalmology program. Costs of in-person examinations are superior in remote areas, 
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as usually includes transportation costs of either patients or healthcare personnel to 
meet eye-screening needs. Hence, the capital cost of the tele-ophthalmology program is 
by far justified in isolated communities through lower personnel and transportation 
costs.      
4.4.4 Strengths and limitations 
To our knowledge, this is the first study that models the introduction of a tele-screening 
program in a semi-urban population without considering exclusive initial use of this 
technology. Although the exclusivity assumption is commonly used in cost-effectiveness 
analyses, it is very unlikely that a new tele-ophthalmology program would entirely 
replace in-person examination in a context where primary care professionals are 
permanently available.18,19 We also contemplated key variables of tele-ophthalmology 
systems such as need for pharmacologic dilation and rate of unreadable images, and 
evaluated their influence on the cost-effectiveness of a category 1 tele-ophthalmology 
program.16  
Our model has some limitations worth noting. First, the present study was tailored to 
the Chatham-Kent community. Patient pool size and prevalence was captured from 
provincial reports; costs were derived from provincial information and administrative 
data from St. Joseph’s healthcare in London (ON). Although aligned with the study 
objectives, such specificity limits the applicability of these results to other settings. 
However, the model structure of this analysis can be used in upcoming studies for the 
evaluation of DR screening programs in similar geographic contexts. Second, the study 
was conducted from a healthcare payer perspective, and indirect costs were not 
included. Nonetheless, a societal perspective would likely favor the implementation of 
tele-ophthalmology due to the inclusion of travel costs avoided and reduced time away 
from work.59 Third, we used number of true positive cases detected (and number of 
cases correctly diagnosed) as our effectiveness outcome. Although this is a clinically 
intuitive measure that provides useful insight regarding the comparative cost-
effectiveness of interventions, it does not reflect the full effectiveness of the program as 
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it does not take into consideration the therapeutic endpoint (e.g cases of blindness 
averted, prevention of SVL). It also limited the direct comparison of our results with 
other studies that used preference-based measures (e.g QALYs).  
4.4.5 Study applicability 
This study opens the discussion as if the benefits of mobile tele-ophthalmology in semi-
urban areas are equivalent to those benefits observed in remote populations. In a semi-
urban community, the implementation of tele-ophthalmology would be almost three 
times more expensive compared to a context where the tele-ophthalmology program is 
assumed to be exclusive. Although our results suggest increased benefits of tele-
ophthalmology versus in-person examination in terms of more patients being screened 
and additional DR cases being detected, the incremental cost of $314 per case may be 
considered too high to be implemented in a publicly funded healthcare system. This is 
largely due to the fact that the healthcare payer would still have to support in-person 
examination in addition to the new telescreening program, especially during early 
stages of program execution.  
If stakeholders are interested in investing on a telescreening program in a semi-urban 
context, a comprehensive discussion about potential strategies to reduce screening 
costs should be in order.60 From the sensitivity analyses, we found that eye specialist 
fees and pupil dilation are the most influential factors in the cost-effectiveness of the 
tele-ophthalmology program. Given that pharmacologic dilation reduces the proportion 
of unnecessary referrals due to unreadable images, a program with pupil dilation to all 
patients will improve cost-effectiveness. Also, the automated detection of DR lesions is 
an alternative to the manual assessment of digital images by a specialist.61  
It is worth noting that our interpretation is based on the incremental cost per case 
detected. Clinical outcomes such as cases of SVL averted or cases of blindness prevented 
were out of the scope of this study. Economic studies based on rural communities have 
found an increased benefit of tele-ophthalmology in terms of clinical outcomes and 
quality of life.25,47,62,63 It is possible that tele-ophthalmology may offer great benefits in 
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terms of cases of SVL averted or QALYs  in a semi-urban context, which would justify the 
initial investment in equipment and labor. Further studies should expand on the analysis 
based on these important clinical endpoints to gain a better understanding about the 
overall benefits of tele-ophthalmology in the semi-urban context. 
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4.6 Tables and figures 
 
 
 
 
 
 
Table 4.1. Base case model parameters and parameter ranges 
Parameter Value 
Range                   
(interval 
for DTA) 
Source 
Fixed Data Elements 
Diabetic population in study 
setting 
10,354 
patients - Booth GL et al, 2012 
Eye examination rate with 
current practice 0.511 - 
Buhrmann, Assaad, Hux, Tang, & 
Sykora, 2003 
Volume increase of screening 
compliance after tele-
ophthalmology is 
implemented 
10% 
increase - 
Olayiwola et al., 2011; Vargas-Sánchez, 
Maldonado-Valenzuela, Pérez-Durillo, 
González-Calvo, & Pérez-Milena, n.d 
 
Variable Data Elements 
Prevalence of any DR in 
Canada 
0.225 0.169 to 
0.281 
National Coalition for Vision Health, 
2007; Public Health Agency of Canada, 
2011 
a) Screening intervention parameters (tele-ophthalmology) 
Figure 4.1 Illustration of a portion of decision tree showing competing alternatives for diabetic 
retinopathy screening. Arm 1 corresponds to current practice (in-person examination); Arm 2 
corresponds to the new intervention evaluated in the model (pharmacy-based tele-
ophthalmology)  
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Proportion prefers  tele-
ophthalmology for DR 
screening 
0.40 0.50; 0.60; 
0.70 
Leese, Newton, Jung, Haining, & 
Ellingford, 1992; Taylor et al., 2007; 
García Serrano et al., n.d. 
Proportion examined with 
tele-ophthalmology* 
0.225 0.169 to 
0.281 
Leese, Newton, Jung, Haining, & 
Ellingford, 1992; Taylor et al., 2007 
Sensitivity  0.84 (95% CI)   
0.76 - 0.91 
Coronado et al., 2013 
Specificity  0.94 (95% CI)   
0.90 - 0.97 
Coronado et al., 2013 
Proportion of dilated 
examinations 
0.337 (95% CI) 
0.25-0.47 
Boucher et al., 2008 
Proportion of unreadable 
images with pupil dilation 
0.054 (95% CI)   
0.033-
0.076 
Coronado et al., 2013 
Proportion of unreadable 
images without pupil dilation  
0.287 (95% CI)   
0.139-
0.435 
Coronado et al., 2013 
b)  Current practice parameters (in-person examination) 
Proportion examined with current 
practice (Pc) after introduction of 
tele-ophthalmology* 
0.337 0.253 to 
0.421 
Leese, Newton, Jung, Haining, & 
Ellingford, 1992; Taylor et al., 2007 
Sensitivity  0.75 (95% CI)    
0.67-0.83 
Olson et al., 2003 
Specificity  0.82 (95% CI)    
0.79-0.86 
Olson et al., 2003 
DTA=Deterministic sensitivity analysis; DR=Diabetic Retinopathy 
* Based on published data estimates about proportion of patients screened after introduction of tele-ophthalmology and 
patient preferences towards examination with tele-ophthalmology. For detailed calculations refer to Appendix I 
 
 
Table 4.2 Estimated costs for in-person examination and pharmacy-based tele-
ophthalmology 
Item Cost per unit Unit description Total cost Data source 
Capital costs*   Cost/year  
Digital Camera $          17,458.50 One retinal camera $            4,032.45 Vendor's quotation 
Table Lift $            1,045.25 One table lift $                241.43 Vendor's quotation 
Software $            1,610.25 One software package $                371.93 Vendor's quotation 
Carrying case $            1,299.50 One carrying case $                300.15 Vendor's quotation 
Maintenance $                460.00 Annual $                460.00 Vendor's quotation 
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maintenance 
Camera transportation costs Cost/year  
Van rent $                  91.07 One cargo van $            1,092.84 Vendor's quotation 
Fuel $                     1.27 One litre $                  76.26 
Ontario Ministry of 
Energy, Ontario prices 
2013 
Overhead costs†   Cost/year  
Pharmacy 
overhead costs $                155.00 
Annual 
expenditures 
per square 
foot 
$                775.00 10th annual Pharmacy Trends Report, 2004 
Labour costs   Cost/patient  Tele-
ophthalmology 
coordinator 
$                  24.18 Hourly wage£ $                    4.03ɸ St. Joseph's Hospital administrative data 
Photographer $                  24.18 Hourly wage£ $                    6.05ɸ St. Joseph's Hospital administrative data 
Grader 
(ophthalmologist) $                  31.66 
Consultation 
per patient $                  31.66 
Alberta Healthcare 
Insurance plan 
Eye care 
specialist $                  51.10 
Consultation 
per patient $                  51.10 
Ontario Ministry of 
Health and Long-term 
Care 
Consumables   Cost/patient  
Referral to retina 
specialist $                111.31 
Examination 
per patient $                111.31 
St. Joseph's Hospital 
administrative data 
Dilation drops- 
Tropicamide 1% $                  16.15 
Cost per unit 
(15 ml) $                     0.54 
St. Joseph's Hospital, 
pharmacy data 
Dilation drops- 
phenylephrine 
2.5% 
$                     4.82 Cost per unit (5 ml) $                  0.120 
St. Joseph's Hospital, 
pharmacy data 
Chin covers $                  56.50 Cost per pack (500) $                  0.113 Vendor's quotation 
*Annualized based on a 5-year life equipment and a 5% depreciation rate                                                                                                                        
†Based on average annual pharmacy overhead expenditures for 5 square feet, adjusted to inﬂaƟon 
£Based on a part-time annual salary of $21,762.  
ɸPart-time salary was extrapolatedaccording to the number of patients per hour. Workload estimation was defined 
based on literature searches (see appendix K) 
 
Table 4.3 Cost ranges used for Deterministic Sensitivity Analysis 
Item Unit description Cost Value or Range†
         
   (for DSA) 
Capital costs 
Digital Camera One retinal camera $           17,458.50 $               29,798.10 
Labour costs       
Tele-ophthalmology 
coordinator 
Consultation per 
patient Hourly wage $24.18 
Photographer Consultation per patient Hourly wage $24.18 
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Grader 
(ophthalmologist) 
Consultation per 
patient  $                     31.66  $ 23.75 to $ 55.41 
Eye care specialist  Consultation per patient  $                      51.10  $ 38.33 to $ 89.43 
† Range based on upper and lower 25% limits 
 
 
 
Table 4.4 Examination outcomes of pharmacy-based tele-ophthalmology and in-person 
examination programs per 10,354 diabetic patients in the study model 
 In-person 
examination 
Introduction of  tele-
ophthalmology 
Patient compliance (%) 51.1% 56.2% 
True positive 893 1029 
True negative 3362 3914 
False positive 738 595 
False negative 298 280 
Total patients screened 5291 5819 
 
 
 
 
Table 4.5 Incremental cost-effectiveness results for in-person examination versus 
introduction of tele-ophthalmology 
Screening 
stategy 
Cost per 
patient  
Incremental 
cost per 
patient 
Effectiveness 
(case 
detected) 
Incremental 
effectiveness ICER Dominance 
In-person 
screening 
(primary care) 
$43.98  0.086   
Undominated 
Introduction of 
Tele-
ophthalmology 
$49.22 $5.24 0.103 0.017 $314.1 Undominated 
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Figure 4.2 Cost-effectiveness plane. In-person examination versus introduction of tele-
ophthalmology 
 
 
 
Figure 4.3 Two way sensitivity analysis. Influence of tele-ophthalmology preference and 
increased patience compliance after introduction of tele-ophthalmology on the 
incremental cost-effectiveness ratio (ICER) 
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Table 4.6 One-way deterministic sensitivity analysis results  
Parameter Base-case value Range 
ICER                              
($/case detected per 
year) 
Prevalence of any diabetic retinopathy 0.225 0.169 to 0.281 $ 394.4 to $ 265.89 
Patient preference for pharmacy-based 
tele-ophthalmology 0.40 0.40 to 0.70 $ 314.15 to $ 236.56 
Diagnostic accuracy in-person 
examination       
Sensitivity 0.75 0.67 to 0.83 $ 282.0 to $ 361.2 
Specificity 0.82 0.79 to 0.86 $ 287.0 to $ 350.2 
Diagnostic accuracy tele-ophthalmology       
Sensitivity 0.84 0.76 to 0.91 $ 405.9 to $ 304.9 
Specificity 0.94 0.90 to 0.97 $ 350.9 to $ 286.6 
Proportion of dilated examinations 
(tele-ophthalmology) 0.337 0.25 to 0.47 $ 333.9 to $ 321.5 
Rate of unreadable images (tele-ophthalmology) 
With pupil dilation 0.054 0.033 to 0.076 $ 306.6 to $ 321.5 
Without pupil dilation 0.287 0.139 to 0.435 $ 209.9 to $ 411.2 
Grader fee per patient (tele-
ophthalmology) $31.66 
$ 23.75 to $ 
55.41 $ 207.6 to $ 633.9 
Tele-ophthalmology coordinator fee per 
patient $4.03 $3.02 to $5.04 $300 to $327.8 
Ophthalmic photographer $6.05 $4.54 to $7.56 $300.05 to $327.8 
In-person consultation 
$51.10 
$ 38.33 to $ 
89.43 
Tele-ophthalmology 
dominates at $ 77 
Referral to retina specialist $111.31 $ 83.48 to $ 139.14 $ 252.5 to $ 375.8 
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Chapter 5  Integrated discussion 
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5.1 Overview 
This chapter outlines the thesis results and implications, and when appropriate it 
expands on the methodology used and interpretation of results. In summary, the 
purpose of this thesis was twofold: To assess the diagnostic accuracy of tele-
ophthalmology for DR screening, and incorporate these findings in an economic model 
to explore the cost-effectiveness of a pharmacy-based tele-ophthalmology program in a 
semi-urban area.   
5.2 Integrated discussion of thesis results 
Chapter 3 of this thesis examined the diagnostic accuracy of tele-ophthalmology 
strategies for DR screening in adults as compared to reference standards. We conducted 
a systematic review in multiple databases from 1998 to 2012 (last update March 2013), 
and performed a meta-analysis categorizing results according to diagnostic threshold 
reported.  
Results suggested that tele-ophthalmology programs fulfilled the minimum 
effectiveness requirements advised by the Canadian Ophthalmological Society 
(sensitivity over 80%, specificity between 90% and 95%).1  For the detection of referable 
DR, we observed that the use of a single field per eye had a negative influence in the 
diagnostic performance of tele-ophthalmology programs, whereas the use of multiple 
photographic fields improved both sensitivity and specificity. For the detection of early  
DR forms, we found that the choice of reference standard affected the study results, in 
that studies that used 7-field fundus photographs (as advised by the American 
Telemedicine Association2) showed better sensitivity compared to studies that selected 
ophthalmologic examination as the reference. This is supported by previous evidence 
that shows that inaccurate reference standards underestimate the diagnostic accuracy 
of a test, being sensitivity more affected than specificity estimates.3,4 We also observed 
that diagnostic performance for the detection of any DR improved over time. This is 
likely attributed to advances of digital camera technologies and data transmission 
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techniques, as a better resolution facilitates the identification of earlier signs of DR, 
reducing the number of false negatives.5    
In Chapter 04, we explored the cost-effectiveness of pharmacy-based tele-
ophthalmology for diabetic retinopathy screening in semi-urban Southwestern Ontario. 
Given that summary accuracy estimates were calculated for the detection of both any 
DR and referable retinopathy, we decided to address the cost-effectiveness of a 
category 1 tele-ophthalmology program, corresponding to the detection of any DR.2 
These estimates were more suitable for the economic model than the results of 
referable DR, since the definition of “any DR” was consistent amongst studies (ETDRS 
≥20). Also, the summary prevalence was less variable across these studies compared to 
studies that used referable retinopathy as screening threshold, and resembled that of 
the Chatham-Kent population. Similarly, we used the meta-analysis information to 
calculate the weighted average of unreadable images according to use of pharmacologic 
dilation and incorporated these values into the economic model.  
We found that pharmacy-based tele-ophthalmology was more costly, but more effective 
than in-person examination, at $478.3 per case detected and an incremental cost-
effectiveness of $314.15 per additional case detected. Sensitivity analyses showed that 
unreadable images and physician’s fees (for both in-person examination and tele-
ophthalmology) influenced cost-effectiveness outcomes. In our model we discarded the 
assumption of exclusive initial use of tele-ophthalmology, as this situation would be 
highly unlikely in a semi-urban area where eye care specialists are permanently 
available. However, if we consider this assumption, the incremental cost-effectiveness 
decreases to $73.23 per additional case detected. 
5.3 Thesis limitations and knowledge gaps in current literature 
Meta-analyses of diagnostic test accuracy studies are particularly challenging as they 
usually incorporate primary studies that differ in study design, levels of quality and 
definition of test positivity.6 Hence, greater variability is expected amongst diagnostic 
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accuracy studies versus clinical trial studies.7 As commented in chapter 03, we detected 
substantial heterogeneity across studies, explored by means of subgroup analyses. 
Amongst studies that detected any DR (category 1), heterogeneity was partially 
explained by the differential use of reference standard and pharmacologic dilation. 
Variability of the summary sensitivity was significantly reduced when low quality studies 
were excluded from the analysis (Base-case I2=90; Q=154 vs. I2=31; Q=8.8) , reflecting 
the influence of study design deficiencies on accuracy estimates. Hence, methodological 
differences in study design, data collection and reporting of diagnostic accuracy 
estimates may account for part of heterogeneity observed in the meta-analysis results 
(methodological bias).8,9  
In contrast to our findings amongst category 1 studies (detection of any DR), 
considerable heterogeneity remained unexplained even after subgroup and sensitivity 
analyses on studies that detected referable DR (category 2). In this case, heterogeneity 
could be partially explained by a threshold effect, since authors in this category used 
diverse guidelines (or even personal criteria) to define test positivity. There may be 
other significant sources of heterogeneity that we could not address in our analysis due 
to the small number of primary studies within subgroups, or lack of adequate reporting 
in primary studies (discussed below).  
Variability due to clinical characteristics was not addressed in this thesis, as this 
information was poorly reported in primary studies. For instance, only 50% of studies 
presented information about ethnicity, type of diabetes and duration of diabetes. Lack 
of clinical and demographic information limits the interpretation of the actual 
usefulness of tele-ophthalmology screening program.  This also impacts the 
interpretability of the economic analysis findings; it could be possible that some patient 
subgroups may have greater benefit from a pharmacy-based tele-screening program. In 
addition to the lack of reporting of clinical characteristics, index technology details such 
as camera resolution, image compression, screen display size and resolution were not 
described in most studies, restricting the assessment of the potential effect of these 
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technological features on the diagnostic performance of screening programs in the 
public health setting. However, we were able to evaluate the influence of number of 
photographic fields per eye and pharmacologic dilation on the diagnostic performance 
of tele-ophthalmology programs, which have been subject of intense debate amongst 
experts regarding their relevance on the diagnostic yield of this procedure.10,11   
Although methodological quality of primary studies was satisfactory, we detected a high 
risk of patient selection bias and risk of bias due to exclusion of patients with 
uninterpretable test results. Most of excluded patients presented comorbidities (e.g 
cataracts) that restricted image interpretation. An inadequate selection of patients, as in 
this case, may lead to an overestimation of sensitivity and specificity.12 Even though this 
is considered a source of bias by some authors, evidence regarding the effect of 
exclusion of patients due to uninterpretable results is very limited, and a definitive 
association with inflated diagnostic accuracy estimates has not been demonstrated.13   
In the economic analysis, we chose the detection of any DR as the threshold for test 
positivity, which by definition corresponds to a Category 1 telehealth program.2 The 
main objective of this program is to increase adherence to screening standards amongst 
diabetic patients, and serve as a platform for surveillance and education of those 
individuals at risk of developing DR. However, direct management and treatment of 
potential cases of severe vision loss correspond to more complex telemedicine 
programs that use additional features such as stereopsis that permit an accurate 
categorization of DR severity levels, including detection of diabetic macular edema.14 
Hence, the interpretation of the cost-effectiveness estimates is limited to the 
incremental cost per additional case detected and the incremental cost per case 
correctly diagnosed.  
Although macular edema is a very important complication from  DR, tele-ophthalmology 
programs without stereopsis (e.g Category 1 and 2 telehealth programs) are technically 
limited to assess this condition.2 However, several studies have found that early clinical 
signs of DR detected in tele-ophthalmology examinations may act as proxy indicators for 
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clinically significant macular edema.15,16 From the meta-analysis, we examined primary 
studies that reported diagnosis of macular edema, and found that 32 out of 33 cases 
were detected along with DR cases.17–19 Hence, a combination of digital photography 
and visual acuity estimation may be useful to evaluate the presence of clinically 
significant macular edema in a category 1 telehealth program. Validation studies must 
be conducted to explore this alternative. 
5.4 Conclusions and future directions 
Our study indicated that diagnostic performance of tele-ophthalmology programs is 
satisfactory and fulfills Canadian Ophthalmological Society’s criteria for DR screening 
(sensitivity >80%, specificity between 90% and 95%)1.  However, the clinical significance 
of these findings is somewhat inconclusive due to the presence of significant 
heterogeneity, which remained partially unexplained after subgroup and sensitivity 
analyses. Hence, careful judgment should be exercised when interpreting the 
applicability of these summary estimates in clinical practice.  
Of note, we found lack of reporting of important clinical characteristics and technology 
features, which in turn limited the assessment of these variables in the meta-analysis. 
This is an issue of paramount importance that should be addressed by investigators and 
journal editors, as an adequate reporting of these features will warrant a 
comprehensive examination of sources of variation in future reviews.20  
Although the diagnostic performance of tele-ophthalmology was satisfactory, the cost-
effectiveness of a pharmacy-based tele-ophthalmology program in a semi-urban 
population is unclear. While this program was more effective than in-person 
examination, an additional cost of $314.1 per case detected may be too high from the 
healthcare payer perspective. Hence, this economic analysis opens the discussion as if 
the benefits of mobile tele-ophthalmology in semi-urban areas are equivalent to those 
benefits observed in remote populations. Prospective studies will provide more insight 
on the impact of such programs on prevention of severe vision loss and quality of life in 
a semi-urban setting. 
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Appendix A. Meta-analysis of Observational Studies in Epidemiology (MOOSE) checklist  
Reporting background should include                                                                             Page 
Problem definition 48 
Hypothesis statement 48 
Description 48 
Type of exposure or intervention used 48, 49 
Type of study designs used 49 
Study population 49 
Reporting of search strategy should include 
Qualifications of searches (e.g. librarians and investigators) 49, 50 
Search strategy, including time period included in the synthesis and 
keywords 
48, 
Appendix C 
Effort to include all available studies, including contact with authors 49,50 
Databases and registries searched 48 
Search software used, name and version, including special features  49 
Use of hand searching (e.g. reference lists of obtained articles) 49 
List of citations located and those excluded including justification 72 
Method of addressing articles published in languages other than English 50 
Method of handling abstracts and unpublished studies - 
Description of any contact with authors 54 
Reporting methods should include 
Description of relevance or appropriateness of studies assembled for 
assessing the hypothesis to be tested 
50 
Rationale for the selection and coding of data (eg, sound clinical principles 
or convenience) 
50 
Documentation of how data were classified and coded (eg, multiple raters, 
blinding, and interrater reliability) 49,50 
Assessment of confounding (eg, comparability of cases and controls in 
studies where appropriate) 
- 
Assessment of study quality, including blinding of quality assessors; 
stratification or regression on possible predictors of study results 51 
Assessment of heterogeneity 52,53 
Description of statistical methods (eg, complete description of fixed or 
random effects models, justification of whether the chosen models account 
for predictors of study results, dose-response models, or cumulative meta-
analysis) in sufficient detail to be replicated 
51, 52 
Provision of appropriate tables and graphics 72-81 
Reporting of results should include 
Graphic summarizing individual study estimates and overall estimate 78, 79 
Table giving descriptive information for each study included 73 
Results of sensitivity testing (eg, subgroup analysis) 81 
Indication of statistical uncertainty of findings 61 
Reporting of discussion should include 
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Quantitative assessment of bias (eg, publication bias) 53 
Justification for exclusion (eg, exclusion of non–English-language citations) 54 
Assessment of quality of included studies 55 
Reporting of conclusions should include 
Consideration of alternative explanations for observed results 60, 61 
Generalization of the conclusions (ie, appropriate for the data presented 
and within the domain of the literature review) 
61 
Guidelines for future research 61 
Disclosure of funding source 54 
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Appendix B. Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) checklist 
 
Section/topic # Checklist item Reported on page # 
TITLE  
Title  1 Identify the report as a systematic review, meta-analysis, or both.  46 
ABSTRACT   
Structured 
summary 2 
Provide a structured summary including, as applicable: background; objectives; data sources; study 
eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; 
limitations; conclusions and implications of key findings; systematic review registration number.  
- 
INTRODUCTION  
Rationale  3 Describe the rationale for the review in the context of what is already known.  48 
Objectives 4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).  
48 
METHODS  
Protocol and 
registration  5 
Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, 
provide registration information including registration number.  
- 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.  
49 
Information 
sources 7 
Describe all information sources (e.g., databases with dates of coverage, contact with study authors to 
identify additional studies) in the search and date last searched.  
48, 49 
Search 8 Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.  
App. C 
Study selection 9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).  
49 
Data collection 
process 10 
Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and 
any processes for obtaining and confirming data from investigators.  
49, 50 
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Data items 11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.  
50 
Risk of bias in 
individual 
studies 
12 
Describe methods used for assessing risk of bias of individual studies (including specification of whether 
this was done at the study or outcome level), and how this information is to be used in any data 
synthesis.  
53 
Summary 
measures 13 
State the principal summary measures (e.g., risk ratio, difference in means).  52 
Synthesis of 
results 14 
Describe the methods of handling data and combining results of studies, if done, including measures of 
consistency (e.g., I2) for each meta-analysis.  
52, 53 
Risk of bias 
across studies 15 
Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, 
selective reporting within studies).  
53, 54 
Additional 
analyses 16 
Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, 
indicating which were pre-specified.  
53 
RESULTS  
Study selection 17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.  
72 
Study 
characteristics 18 
For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up 
period) and provide the citations.  
73 
Risk of bias 
within studies 19 
Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  77, 78, 83 
Results of 
individual 
studies 
20 
For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for 
each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
78, 79 
Synthesis of 
results 21 
Present results of each meta-analysis done, including confidence intervals and measures of consistency.  79 
Risk of bias 
across studies 22 
Present results of any assessment of risk of bias across studies (see Item 15).  77, 78 
Additional 23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see 81, 82 
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analysis Item 16]).  
DISCUSSION  
Summary of 
evidence 24 
Summarize the main findings including the strength of evidence for each main outcome; consider their 
relevance to key groups (e.g., healthcare providers, users, and policy makers).  
59 
Limitations 25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).  
60 
Conclusions 26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.  
61 
FUNDING 
Funding 27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.  
54 
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Appendix C Complete search strategies for primary databases 
 
C.1. Medline search strategy (OVID) 
 
 
C.2. EMBASE search strategy (OVID) 
 
# Search terms 
1 Diabetic Retinopathy/ or retina macula edema/ or eye fundus/ 
2 (diabetic retinopath$ or diabetic maculopath$ or macular edema or macular 
oedema or macula edema or macula oedema or fovea edema or fovea oedema 
or fundus oculi).mp. 
3 (fundus adj5 (eye or retina$)).mp. 
4 1 or 2 or 3 
5 exp Diagnosis/ or diagnostic imaging/ 
6 diagnos$.mp. 
7 5 or 6 
# Search terms 
1 Diabetic Retinopathy/ or macular edema/ or fundus oculi/ 
2 (diabetic retinopath$ or diabetic maculopath$ or macular edema or macular 
oedema or fovea edema or fovea oedema or fundus oculi).mp. [mp=title, 
abstract, original title, name of substance word, subject heading word, protocol 
supplementary concept, rare disease supplementary concept, unique identifier] 
3 (fundus adj10 (eye or retina$)).mp. [mp=title, abstract, original title, name of 
substance word, subject heading word, protocol supplementary concept, rare 
disease supplementary concept, unique identifier] 
4 1 or 2 or 3 
5 exp Diagnosis/ or diagnostic imaging/ 
6 diagnos$.mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, protocol supplementary concept, rare disease 
supplementary concept, unique identifier] 
7 5 or 6 
8 telemedicine/ or telepathology/ or photography/ or vision screening/ 
9 (telescreen$ or automated screen$ or digital imag$ or tele-screen$ or 
teleophthalmology or tele-ophthalmology or digital screen$ or photograph$ or 
vision screen$ or image anal$ or telemedicine or telepathology or teleconsult$ 
or tele-consult$ or telehealth).mp. 
10 8 or 9 
11 exp "Sensitivity and Specificity"/ or comparative effectiveness research/ or exp 
evaluation studies as topic/ 
12 (sensitiv$ and specificit$).mp. 
13 evaluation studies.pt. 
14 evaluation stud$.mp. 
15 11 or 12 or 13 or 14 
16 1 and 7 and 10 and 15 
17 Limit 16 to yr=”1998-Current” 
132 
 
 
8 telemedicine/ or teleconsultation/ or telehealth/ or telepathology/ or exp 
medical photography/ or image analysis/ or vision test/ 
9 (telescreen$ or automated screen$ or digital imag$ or tele-screen$ or telehealth 
or teleconsult$ or tele-consult$ or teleophthalmology or tele-ophthalmology or 
digital screen$ or medical photograph$ or vision screen$ or image anal$ or 
telemedicine or telepathology).mp. 
10 8 or 9 
11 "Sensitivity and Specificity"/ or Comparative Studies/ or Comparative 
Effectiveness/ or Evaluation/ 
12 (sensitiv$ and specificit$).mp. 
13 (Comparative stud$ or comparative effectiveness or evaluat$).mp. 
14 11 or 12 or 13 
15 4 and 7 and 10 and 14 
16  limit 20 to yr="1998 -Current" 
 
C.3. BIOSIS search strategy (Web of Knowledge) 
 
 
 
C.4.  Web of Science search strategy (Web of knowledge) 
 
# Search terms 
#1 “diabetic retinopath*” or ”diabetic maculopath*” or “macular edema” or 
“macular oedema” or “fovea edema” or “fovea oedema” or “fundus oculi” 
#2 fundus same (eye or retina*) 
# Search terms 
#1 “diabetic retinopath*” or ”diabetic maculopath*” or “macular edema” or 
“macular oedema” or “fovea edema” or “fovea oedema” or “fundus oculi” 
#2 fundus same (eye or retina*) 
#3 #1 or #2 
#4 Concept Codes=(Pathology - Diagnostic) OR Topic=(diagnos*) 
#5 Concept Codes=(Methods - Photography OR Public health - Health services 
"and" medical care) 
#6 telescreen* or “automated screen*” or “digital imag*” or tele-screen* or 
teleophthalmology or tele-ophthalmology or “digital screen*” or photograph* 
or “vision screen*” or “image anal*” or telemedicine or telehealth or 
telepathology or teleconsult* or  ”tele-consult*” 
#7 #5 or #6 
#8 “comparative stud*" or "evaluation research" or "evaluation stud*" or 
"comparative effectiveness" or (sensitiv* SAME specific*) 
#9 #8 AND #7 AND #4 AND #3 
Timespan=1998-2012. Databases=BIOSIS Previews.  
Lemmatization=On    
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#3 #1 or #2 
#4 diagnos* 
#5 telehealth or teleconsult* or “tele-consult*” or telescreen* or "automated 
screen*" or "digital imag*" or “tele-screen*” or teleophthalmology or tele-
ophthalmology or "digital screen*" or photograph* or "vision screen*" or 
"image anal*" or telemedicine or telepathology 
#6 “comparative stud*" or "evaluation research" or "evaluation stud*" or 
"comparative effectiveness" or (sensitiv* SAME specific*) 
#7 #6 AND #5 AND #4 AND #3 
 
  
  
  
C.5. Cochrane library search strategy (Wiley online library) 
 
# Search terms 
#1 MeSH descriptor Diabetic Retinopathy, this term only  
#2 MeSH descriptor Macular Edema, this term only  
#3 MeSH descriptor Fundus Oculi, this term only 
#4 “diabetic retinopathy” or “diabetic retinopathies” or “diabetic maculopathy” 
or “diabetic maculopathies” or macular edema or macular oedema or fovea 
edema or fovea oedema or fundus oculi  NEED “ “ around all phrases, eg 
“fovea edema” 
#5 Fundus NEAR/5 (eye OR retina*) 
#6 #1 or #2 or #3 or #4 or #5 
#7 MeSH descriptor Diagnosis explode all trees  
#8 MeSH descriptor Diagnostic Imaging, this term only 
#9 diagnos* 
#10 #7 or #8 or #9 
#11 MeSH descriptor Telemedicine, this term only  
#12 MeSH descriptor Telepathology, this term only  
#13 MeSH descriptor Photography, this term only  
#14 MeSH descriptor Vision screening, this term only  
#15 telemedicine or telehealth or teleconsult or teleconsultation or "tele-consult" 
or "tele-consultation" or telescreen or telescreening or "automated screen" or 
"automated screening" or "digital images" or "digital imaging" or "digital 
image" or "tele-screen" or "tele-screening" or teleophthalmology or "tele-
ophthalmology" or "digital screen" or "digital screening" or photography or 
photographic or "vision screening" or "vision screen" or "image analysis" or 
telepathology 
#16 #11 or #12 or #13 or #14 or #15 
#17 MeSH descriptor Sensitivity and Specificity explode all trees  
#18 MeSH descriptor Comparative Effectiveness Research, this term only  
#19 MeSH descriptor Evaluation Studies as Topic explode all trees  
#20 (evaluation studies):pt  
#21 (sensitiv* and specificit*) or "comparative effectiveness" OR "evaluation 
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study" or "evaluation studies" or evaluat* 
#22 #17 OR #18 OR #19 OR #20 OR #21 
#23 #6 and #10 and #16 and #22 from 1998 to 2012 
 
 
C.6. CINAHL Search strategy (EBSCO host) 
 
 
 
 
 
 
 
# Search terms 
S1 MH "Diabetic Retinopathy" 
S2 diabetic retinopath* or diabetic maculopath* or macular edema or macular 
oedema or fovea edema or fovea oedema or fundus oculi NEED “ “ around all 
phrases, eg “macular edema” 
S3 fundus N10 (eye or retina*) 
S4 S1 or S2 or S3 
S5 MH "Diagnosis" OR MH "Diagnosis, Eye+" OR MH "Diagnostic Imaging" 
S6 Diagnos* 
S7 S5 or S6 
S8 MH "Telehealth" OR MH "Telemedicine" OR MH "Remote Consultation" OR 
MH "Telepathology" OR MH "Photography" OR MH "Digital Imaging"  OR MH 
"Vision Screening" 
S9 telescreen* or automated screen* or digital imag* or tele-screen* or 
teleophthalmology or tele-ophthalmology or digital screen* or photograph* 
or vision screen* or image anal* or telehealth or telepathology or 
telemedicine or teleconsult* or “tele-consult*” or “remote consult*”  NEED “ 
“ around all phrases, eg “automated screen*” 
S10 S8 or S9 
S11 MH "Sensitivity and Specificity" OR MH "Comparative Studies" OR MH 
"Evaluation Research" OR MH "Summative Evaluation Research"  
S12 sensitiv* and specificit* 
S13 evaluation stud*  NEED “ “ around all phrases, 
S14 S11 or S12 or S13 
S15 S4 and S7 and S10 and S14 
S16 S4 and S7 and S10 and S14 
Limiters - Published Date from: 19980101-20121231 
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Appendix D. Data collection form 
 
 
 
 
1. Study features 
 
a) Citation (author, year) 
 
b) Country 
 
c) Language 
 
d) Study objective 
 
e) Funding source 
 
2. Sample characteristics 
 
a) Patient recruitment 
 
b) Inclusion/exclusion criteria 
 
c) Number of patients approached 
 
d) Number of patients fully screened 
 
e) Demographics 
 
 
  
Yes  No Not reported 
Mean (SD) OR Median (range) OR 
proportion 
Age         
Race/ethnicity       Caucasian African-American Hispanic Other 
              
Type I diabetes         
Type II diabetes         
Visual acuity         
Any diabetic 
retinopathy prevalence         
Referable diabetic 
retinopathy prevalence         
Patient diagnosis         
Definition of referable diabetic retinopathy (if applicable) 
 
Diagnostic accuracy of tele-ophthalmology for diabetic retinopathy screening 
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f) Unit of study  
 
 
 
 
3. Screening details 
 
 
a) Reference standard used 
 
7-field ETDRS photographs   
Slit-lamp biomicroscopy   
Not reported  
 
b) Grading guideline used 
 
Modified Airlie House Classification   
European Field Guide   
International Clinical Diabetic Retinopathy Scale   
Other (please specify)   
Not reported  
 
c) Index technology 
 
i. Fundus camera 
 
Camera brand   
Camera resolution   
 
ii. Image acquisition (be as specific as possible) 
 
Technician: 
Certified photographer   
Nurse   
Eye care professional   
Other (please specify)   
Not reported  
 
 
Number of fields taken per eye: 
One   
Two   
Three   
Eye   
Patient   
   Not reported   
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Four   
Five   
More than five   
Not reported   
 
Field positioning: 
 
Stereopsis 
Yes   
No   
Not reported   
 
Pupil dilation 
Yes/mixed   
No   
Not reported   
 
Mydriatic agent (if applicable): 
 
iii. Image quality 
 
   Yes No 
Not 
reported 
Proportion OR 
compression ratio 
Unreadable images (%)         
Image compression         
 
 
4. Diagnostic accuracy 
 
 
5. Additional comments of the reviewer 
 
 
 
 
 
 
 
 
 
 
 
  
Sensitivity 
(95% CI) 
Specificity 
(95% CI) TP FN FP TN 
Any Diabetic Retinopathy             
Referable Diabetic Retinopathy             
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Appendix E. Adapted QUADAS2 criteria  
 
Phase 1: State the review question 
Author:  
Index test(s): 
Reference standard: 
Unit of study: 
Phase 2: Draw a flow diagram for the 
primary study 
 
Phase 3: Risk of bias judgments        
 
DOMAIN 1: Patient selection      
a. Describe methods of patient 
selection: 
 
b. Signaling questions  
Grading: If at least one “No”, then Risk of 
bias is HIGH. If at least one “Unclear”, 
then Risk of bias is “UNCLEAR”. 
 
1) Was a consecutive or random 
sample of patients enrolled? 
 
Yes  
No  
Unclear  
 
 
2) Did the study avoid inappropriate 
exclusions? 
 
Yes  
No  
Unclear  
 
Could the selection of patients have 
introduced bias? 
RISK:   
HIGH  
LOW  
UNCLEAR  
 
 
DOMAIN 2: Index test(s)    
Please complete for each index test 
 
a. Describe the index test and how it 
was conducted and interpreted: 
 
b. Signalling questions  
 
Grading: If at least one “No”, then Risk of 
bias is HIGH. If at least one “Unclear”, 
then Risk of bias is “UNCLEAR”. 
 
3) Were the index test results 
interpreted without knowledge of 
the results of the reference 
standard? 
 
Yes  
No  
Unclear  
 
4) If a threshold was used, was it 
pre-specified? 
 
Yes  
No  
Unclear  
 
Could the conduct or interpretation of 
the index test have introduced bias? 
RISK:   
HIGH  
LOW  
UNCLEAR  
 
DOMAIN 3: Reference standard       
a. Describe the reference standard 
and how it was conducted and 
interpreted: 
 
b. Signalling questions  
Grading: If at least one “No”, then Risk of 
bias is HIGH. If at least one “Unclear”, 
then Risk of bias is “UNCLEAR”. 
 
5) Is the reference standard likely to 
correctly classify the target 
condition? 
 
Yes  
No  
Unclear  
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6) Were the reference standard 
results interpreted without 
knowledge of the results of the 
index test? 
 
Yes  
No  
Unclear  
 
Could the reference standard, its 
conduct, or its interpretation have 
introduced bias? 
RISK:  
HIGH  
LOW  
UNCLEAR  
 
 
DOMAIN 4: Flow and timing    
a. Describe any patients who did not 
receive the index test(s) and/or 
reference standard or who were 
excluded from the 2x2 table (refer 
to flow diagram) 
 
b. Describe the time interval or any 
interventions between index 
test(s) and the reference standard 
 
c. Signaling questions  
Grading: If at least one “No”, then Risk of 
bias is HIGH. If at least one “Unclear”, 
then Risk of bias is “UNCLEAR”. 
 
7) Was there an appropriate interval 
link between index test(s) and 
reference standard? 
 
Yes  
No  
Unclear  
 
 
8) Did all patients receive the same 
reference standards? 
Yes  
No  
Unclear  
 
9) Were all patients included in the 
analysis? 
 
Yes  
No  
Unclear  
 
Could the patient flow have introduced 
bias? 
RISK:  HIGH/LOW/UNCLEAR 
 
HIGH  
LOW  
UNCLEAR  
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Appendix F. Paired forest plots – Sensitivity analyses of included studies per category (category 1, detection of any diabetic retinopathy; 
category 2, detection of referable diabetic retinopathy) 
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Figure 1a Category 1 studies – sensitivity analysis excluding studies with 
high/uncertain risk of bias as graded by QUADAS2 criteria 
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Figure 1b Category 1 studies – sensitivity analysis excluding studies 
published prior 2005 
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Appendix F. (Continued)
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Figure 2a Category 2 studies – sensitivity analysis excluding studies with 
high/uncertain risk of bias as graded by QUADAS2 criteria 
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Figure 2b Category 2 studies – sensitivity analysis excluding studies 
published prior 2005 
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Appendix G.  Decision tree model for tele-ophthalmology versus in person examination 
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Appendix H. Search strategy (Pubmed and EMBASE). Compliance after introduction of 
mobile units for eye assessment and patient preferences for screening with mobile units 
 
H.1 Medline 
 Search terms 
1 *Telemedicine/ or exp Mobile Health Units/ or exp Community Pharmacy 
Services/ 
2 (tele-medicine or tele-screening or telescreening or mobile health unit$ or 
community pharmac$ service$).mp. 
3 1 or 2 
4 Eye diseases/ or Ophthalmology/ or Retinal Diseases/ or Retina/pa or exp 
Diabetic Retinopathy/ 
5 (eye disease$ or retinal disease$ or retina$ or diabetic retinopath$).mp. 
6 4 or 5 
7 Mass Screening/ or diagnosis/ or early diagnosis/ 
8 3 and 6 and 7 
 
H.2 Embase  
 Search terms 
1 telediagnosis/ or telemedicine/ or preventive health service/ 
2 (telediagnos$ or telemedicine or tele-medicine or telescreening or tele-
screening or preventive health service$).mp. 
3 1 or 2 
4 eye disease/ or retina disease/ or diabetic retinopathy/ 
5 (eye disease$ or retina disease$ or retina$ or diabetic retinopath$).mp. 
6 4 or 5 
7 diagnosis/ or early diagnosis/ or exp mass screening/ 
8 3 and 6 and 7 
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Appendix I. Calculation of model probabilities 
 
I.1 Calculation of screening probabilities for in-person examination (Arm 1) and tele-
ophthalmology (Arm 2) 
 
I.1.1 In-person examination (Arm 1) 
 
P(ref)= 0.511    Ontario examination rate of diabetic patients one year after receiving a 
diabetes diagnosis (Buhrmann et al., 2003)  
 
Proportion of non-compliant patients is defined as 1- P(ref) = 0.489 
 
I.1.2 Tele-ophthalmology screening (Arm 2) 
 
From the literature search (Appendix H) it is assumed a 10% volume increase (V) of 
screening examinations after introduction of mobile retinal screening (Olayiwola JN et 
al., 2011). 
We have the following screening rate after introduction of tele-ophthalmology 
             P(Arm 2)= P(ref) х V 
Where,  
V= Volume increase of screening examinations after introduction of mobile retinal 
screening. 
 
P(Arm 2)= 0.511 x 1.10= 0.5621 
 
I.1.2.1 Proportion of tele-ophthalmology examinations within Arm 2 
To calculate the proportion of examinations with tele-ophthalmology within Arm 2 we 
have the following 
 
 P(tele)= T ( P(ref) х V )   , V ≥ 1, P(tele) <1 
Where,  
T= Proportion of patients that accept a tele-ophthalmology examination 
 
From the literature search (Appendix H) we assumed that 40% of screened patients 
accepted a tele-ophthalmology examination (T), and the remaining 60% preferred the 
in-person examination. 
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P(tele)= 0.40 (0.5621)= 0.2248 
 
I.1.2.2 Proportion of in-person examinations within Arm 2 
The proportion of in-person examinations (P(inp)) is defined as 
P(inp)= P(Arm 2) - P(tele) 
P(inp)= 0.3373 
 
I.1.2.3 Proportion of non-compliant patients 
Proportion of non-compliant patients is defined as 
P(nc)= 1- P(Arm2) 
P(nc)= 0.4379 
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Appendix J. Summary of probabilities incorporated in the economic model 
Notation Details Value 
Base tree     
p Patients screened with current practice (Arm 1) 0.511 
1-p Patients not screened (Arm 1) 0.489 
q Patients would prefer in-person examination over 
tele-ophthalmology 
0.60 
1-q Patients would prefer tele-ophthalmology 0.40 
p(n) Patients screened after implementation of tele-
ophthalmology (Arm 2) 
0.5621 
[p(n)]*[q] Patients screened with in-person examination 
(Arm 2) 
0.3373 
[p(n)]*[1-q] Patients screened with tele-ophthalmology (Arm 
2) 
0.2248 
1-[(6)+(7)] Patients not screened (after tele-ophthalmology) 0.4379 
In-person examination     
se_primary Test "+" (among diseased) 0.75 
1-[se_primary] Test "-" (among diseased) 0.25 
sp_primary Test "-" (among non-diseased) 0.82 
1-[sp_primary] Test "+" (among non-diseased) 0.18 
Tele-ophthalmology   
d Patients with dilated examination 0.337 
1-d Patients with undilated examination 0.663 
u_d Unreadable images with pupil dilation 0.0547 
1-[u_d] Readable images with pupil dilation 0.9453 
u_nod Unreadable images without dilation  0.2874 
1-[u_nod] Readable images without dilation 0.7126 
se_tele Test "+" (among diseased) 0.89 
1-[se_tele] Test "-" (among diseased) 0.11 
sp_tele Test "-" (among non-diseased) 0.94 
1-[sp_tele] Test "+" (among non-diseased) 0.06 
     
DR_yes Proportion with any DR (prevalence) 0.225 
1-[DR_yes] Not diseased 0.775 
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Appendix K. Search strategy (Medline, Embase) 
 
K.1 Medline 
 
      # Search terms 
1 Diabetic Retinopathy/ or macular edema/ or fundus oculi/ 
2 (diabetic retinopath$ or diabetic maculopath$ or macular edema or 
macular oedema or fovea edema or fovea oedema or fundus 
oculi).mp. 
3 1 or 2 
4 exp Diagnosis/ or diagnostic imaging/ 
5 (diagnos$ or screen$).mp. 
6 4 or 5 
7 "costs and cost analysis"/ or "cost allocation"/ or cost-benefit analysis/ 
or exp "cost control"/ or health care costs/ or direct service costs/ or 
employer health costs/ or hospital costs/ or exp health expenditures/ 
or Decision Trees/ or markov chains/ 
8 (cost-effective$ or cost effective$ or cost-benefit or cost benefit or 
decision tree$ or markov model$ or economic analys$).mp. 
9 7 or 8 
10 3 and 6 and 9 
11 Diabetic Retinopathy/ec [Economics] 
12 10 or 11 
 
K.2 Embase 
 
# Search terms 
1 Diabetic Retinopathy/ or retina macula edema/ or eye fundus/ 
2 (diabetic retinopath$ or diabetic maculopath$ or macular edema or 
macular oedema or macula edema or macula oedema or fovea edema 
or fovea oedema or fundus oculi).mp. 
3 1 or 2 
4 exp Diagnosis/ or diagnostic imaging/ 
5 diagnos$.mp. 
6 4 or 5 
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7 *"cost effectiveness analysis"/ 
8 economic evaluation/ or health care cost/ or decision tree/ 
9 7 or 8 
10 (cost-effective$ or cost effective$ or decision tree$ or economic 
analys$).mp. 
11 9 or 10 
12 3 and 6 and 11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
149 
 
 
Curriculum Vitae 
 
Name: Andrea Catalina Coronado 
Post-secondary 
Education and Degrees: 
Western University 
London, Canada 
2011-2014   M.Sc 
 Universidad de Los Andes 
Bogota, Colombia 
2005-2010   B.Sc (Hons) 
Honours and Awards: Best Science Student Research Presentation 
Ophthalmology Research Day – Western University 
2012 
 Ontario Graduate Scholarship (OGS) 
Ministry of Training, Colleges and Universities 
2012-2013 
 Schulich Graduate Scholarship 
Western University 
2011-2013 
Peer Reviewed 
Abstracts: 
"Effectiveness of Telemedicine Strategies for Diabetic Retinopathy 
Diagnosis: A Systematic Review".  
Association for Research in Vision and Ophthalmology (ARVO) Annual 
Meeting. Seattle, Washington State (US). May 5th-9th, 2013  Presenter 
 “Influence of Pupil Dilation on Tele-screening Strategies for Diabetic 
Retinopathy Assessment”.  
Canadian Society of Epidemiology and Biostatistics (CSEB) Biennial 
Conference. St. John’s, Newfoundland (Canada). June 25th-27th, 2013 
Presenter 
 
 
